51
|
Sunny A, Rustveld L. The Role of Patient Navigation on Colorectal Cancer Screening Completion and Education: a Review of the Literature. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2018; 33:251-259. [PMID: 27878766 DOI: 10.1007/s13187-016-1140-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Although the general assumption is that patient navigation helps patients adhere to CRC screening recommendations, concrete evidence for its effectiveness is still currently under investigation. The present literature review was conducted to explore effectiveness of patient navigation and education on colorectal cancer (CRC) screening completion in medically underserved populations. Data collection included PubMed, Google Scholar, and Cochrane reviews searches. Study inclusion criteria included randomized controlled trials and prospective investigations that included an intervention and control group. Case series, brief communications, commentaries, case reports, and uncontrolled studies were excluded. Twenty-seven of the 36 studies screened for relevance were selected for inclusion. Most studies explored the utility of lay and clinic-based patient navigation. Others implemented interventions that included tailored messaging, and culturally and linguistically appropriate outreach and education efforts to meet CRC screening needs of medically underserved individuals. More recent studies have begun to conduct cost-effectiveness analyses of patient navigation programs that impacted CRC screening and completion. Peer-reviewed publications consistently indicate a positive impact of patient navigation programs on CRC screening completion, as well have provided preliminary evidence for their cost-effectiveness.
Collapse
Affiliation(s)
- Ajeesh Sunny
- Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Luis Rustveld
- Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX, USA.
| |
Collapse
|
52
|
McBrien KA, Ivers N, Barnieh L, Bailey JJ, Lorenzetti DL, Nicholas D, Tonelli M, Hemmelgarn B, Lewanczuk R, Edwards A, Braun T, Manns B. Patient navigators for people with chronic disease: A systematic review. PLoS One 2018; 13:e0191980. [PMID: 29462179 PMCID: PMC5819768 DOI: 10.1371/journal.pone.0191980] [Citation(s) in RCA: 153] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Accepted: 01/14/2018] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND People with chronic diseases experience barriers to managing their diseases and accessing available health services. Patient navigator programs are increasingly being used to help people with chronic diseases navigate and access health services. OBJECTIVE The objective of this review was to summarize the evidence for patient navigator programs in people with a broad range of chronic diseases, compared to usual care. METHODS We searched MEDLINE, EMBASE, CENTRAL, CINAHL, PsycINFO, and Social Work Abstracts from inception to August 23, 2017. We also searched the reference lists of included articles. We included original reports of randomized controlled trials of patient navigator programs compared to usual care for adult and pediatric patients with any one of a defined set of chronic diseases. RESULTS From a total of 14,672 abstracts, 67 unique studies fit our inclusion criteria. Of these, 44 were in cancer, 8 in diabetes, 7 in HIV/AIDS, 4 in cardiovascular disease, 2 in chronic kidney disease, 1 in dementia and 1 in patients with more than one condition. Program characteristics varied considerably. Primary outcomes were most commonly process measures, and 45 of 67 studies reported a statistically significant improvement in the primary outcome. CONCLUSION Our findings indicate that patient navigator programs improve processes of care, although few studies assessed patient experience, clinical outcomes or costs. The inability to definitively outline successful components remains a key uncertainty in the use of patient navigator programs across chronic diseases. Given the increasing popularity of patient navigators, future studies should use a consistent definition for patient navigation and determine which elements of this intervention are most likely to lead to improved outcomes. TRIAL REGISTRATION PROSPERO #CRD42013005857.
Collapse
Affiliation(s)
- Kerry A. McBrien
- Departments of Family Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | - Noah Ivers
- Department of Family and Community Medicine, Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Lianne Barnieh
- Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Jacob J. Bailey
- W21C Research and Innovation Centre, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Diane L. Lorenzetti
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | - David Nicholas
- Faculty of Social Work, University of Calgary, Calgary, Alberta, Canada
| | - Marcello Tonelli
- Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Brenda Hemmelgarn
- Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | - Richard Lewanczuk
- Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, Alberta, Canada
| | - Alun Edwards
- Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Ted Braun
- Department of Family Medicine, Alberta Health Services, Calgary, Alberta, Canada
| | - Braden Manns
- Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
53
|
Lee SJC, Inrig SJ, Balasubramanian BA, Skinner CS, Higashi RT, McCallister K, Bishop WP, Santini NO, Tiro JA. Identifying quality improvement targets to facilitate colorectal cancer screening completion. Prev Med Rep 2018. [PMID: 29527466 PMCID: PMC5840842 DOI: 10.1016/j.pmedr.2018.01.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The colorectal cancer (CRC) screening process involves multiple interfaces (communication exchanges and transfers of responsibility for specific actions) among primary care and gastroenterology providers, laboratory, and administrative staff. After a retrospective electronic health record (EHR) analysis discovered substantial clinic variation and low CRC screening prevalence overall in an urban, integrated safety-net system, we launched a qualitative analysis to identify potential quality improvement targets to enhance fecal immunochemical test (FIT) completion, the system's preferred screening modality. Here, we report examination of organization-, clinic-, and provider-level interfaces over a three-year period (December 2011–October 2014). We deployed in parallel 3 qualitative data collection methods: (1) structured observation (90+ hours, 10 sites); (2) document analysis (n > 100); and (3) semi-structured interviews (n = 41) and conducted iterative thematic analysis in which findings from each method cross-informed subsequent data collection. Thematic analysis was guided by a conceptual model and applied deductive and inductive codes. There was substantial variation in protocols for distributing and returning FIT kits both within and across clinics. Providers, clinic and laboratory staff had differing access to important data about FIT results based on clinical information system used and this affected results reporting. Communication and coordination during electronic referrals for diagnostic colonoscopy was suboptimal particularly for co-morbid patients needing anesthesia clearance. Our multi-level approach elucidated organizational deficiencies not evident by quantitative analysis alone. Findings indicate potential quality improvement intervention targets including: (1) best-practices implementation across clinics; (2) detailed communication to providers about FIT results; and (3) creation of EHR alerts to resolve pending colonoscopy referrals before they expire. Multi-level qualitative approach identified challenges to 3 clinical processes Variation in fecal immunochemical testing (FIT) kit distribution and return Incomplete transfer of key FIT result data across clinical information systems Suboptimal communication and coordination during colonoscopy referrals
Collapse
Affiliation(s)
- Simon J Craddock Lee
- Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA.,Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA
| | - Stephen J Inrig
- Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA.,Mount St. Mary's University, Los Angeles, CA, USA
| | - Bijal A Balasubramanian
- Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA.,Department of Epidemiology, Human Genetics, and Environmental Sciences, UT Health School of Public Health - Dallas Campus, Dallas, TX, USA
| | - Celette Sugg Skinner
- Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA.,Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA
| | - Robin T Higashi
- Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA
| | | | - Wendy Pechero Bishop
- Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA.,Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA
| | | | - Jasmin A Tiro
- Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA.,Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA
| |
Collapse
|
54
|
Disparities in women's cancer-related quality of life by Southern Appalachian residence. Qual Life Res 2018; 27:1347-1356. [PMID: 29374856 PMCID: PMC5891549 DOI: 10.1007/s11136-018-1793-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/22/2018] [Indexed: 11/02/2022]
Abstract
PURPOSE The purpose was to determine whether Appalachian residence alone or in combination with violence was linked to poorer quality of life (QOL). METHODS Women recently diagnosed and included in either the Kentucky or North Carolina Cancer Registries were interviewed by phone between 2009 and 2015 (n = 3320; mean age = 56.74). Response rates were similar by state (40.1 in Kentucky and 40.9% in North Carolina). Appalachian (N = 990) versus non-Appalachian residents (N = 2330) were hypothesized to have poorer QOL defined as (a) lower Functional Assessment of Cancer Therapy-General (FACT-G) scores and (b) more symptoms of depression, stress, or comorbid physical conditions. Lifetime intimate partner or sexual violence was first investigated as a moderator then mediator of regional differences. Multiple analyses of covariance (MANCOVA) models were used. RESULTS Violence modified the effect of Appalachian residence on poorer QOL outcomes; FACT-G total scores (p = .02) were lowest for women living in Appalachia who had additionally experienced violence. Socioeconomic indicators appeared to mediate or explain differences in QOL outcomes by Appalachian residence such that when adjusting for income, education and insurance, Appalachian residence remained associated only with poorer physical QOL outcomes (p < .05). CONCLUSIONS While violence rates did not differ by residence, the combined effect of living in Appalachia and experiencing violence resulted in significantly greater impact on poorer QOL among women recently diagnosed with cancer. Clinical consideration of patients' residence, socioeconomic status and violence experienced may help identify and mitigate the longer-term impact of these identifiable factors associated with poorer QOL.
Collapse
|
55
|
Delivery of adjuvant chemotherapy among stage III colon cancer patients at a public versus private hospital in New York City. Cancer Causes Control 2017; 29:253-260. [PMID: 29250702 DOI: 10.1007/s10552-017-0996-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 12/13/2017] [Indexed: 11/27/2022]
Abstract
PURPOSE Prior studies of timeliness of adjuvant chemotherapy (AC) initiation in stage III colon cancer have suggested longer time to AC at public compared with private hospitals. Few studies have explored differences in AC completion. We investigated whether timely initiation and completion of AC differed between a public and private hospital, affiliated with the same academic institution in a large, urban setting. METHODS We conducted a retrospective cohort study of stage III colon cancer patients who had surgery and AC at the same medical center between 2008 and 2015, either at its affiliated public hospital (n = 43) or private hospital (n = 79). We defined timely initiation as receiving AC within 60 days postoperatively, and completion as receiving ≥ 75% of planned AC. Univariate and stepwise multivariable logistic regressions were used to identify factors associated with AC delivery. RESULTS Median number of days to AC was significantly greater among patients at the public (53, range 31-231) compared with the private hospital (43, range 25-105; p = 0.002). However, the percentage of patients with timely AC initiation did not differ substantially by hospital (74 vs 81%, p = 0.40). In multivariable analysis, age (OR 0.95/year, 95% CI 0.91-0.99) and laparoscopic versus open surgery (OR 5.65, 95% CI 1.92-16.62) were significant factors associated with timely AC initiation. Moreover, AC completion did not differ significantly between public (83.7%) and private (89.9%) hospital patients (p = 0.32). CONCLUSIONS The proportions of patients with timely initiation and completion of AC were similar at a public and private hospital affiliated with a large, urban medical center. Future research should investigate how specific system-level factors help alleviate this expected difference in timely care delivery.
Collapse
|
56
|
Riogi B, Wasike R, Saidi H. Effect of a breast navigation programme in a teaching hospital in Africa. SOUTH AFRICAN JOURNAL OF ONCOLOGY 2017. [DOI: 10.4102/sajo.v1i0.30] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
<strong>Background:</strong> Breast cancer screening programmes have been developed in few developing countries to aid curb the increasing burden. However, breast cancer is still being detected in late stage, attributed to barriers in health care. Patient navigation programmes have been implemented in developed countries to help patients overcome these barriers, and they have been associated with early detection and timely diagnosis. Despite the consistent positive effects of breast navigation programmes, there are no studies conducted to show its effect in Africa where the needs are enormous.<br /><strong>Aim:</strong> To evaluate the effect of patient navigation programme on patient return after an abnormal clinical breast cancer screening examination finding at Aga Khan University Hospital, Nairobi(AKUH-N).<br /><strong>Setting:</strong> Women presenting for breast screening.<br /><strong>Methods:</strong> This was a before-and-after study conducted on 76 patients before and after the implementation of the navigation programme. They were followed up for 30 days. Measures included proportion of patient return and time to return.<br /><strong>Results:</strong> The proportion of return of patients in the navigated and non-navigated group was 57.9% and 23.7%, respectively (odds ratio [OR]: 4.43 [95% confidence interval, CI: 1.54– 12.78]; <em>p</em> = 0.0026).The proportion of timely return in the navigated group was 90.1% and 77.8% for the non-navigated group (OR: 2.85 [95% CI: 0.34–24.30], <em>p</em> = 0.34). The mean time to return in the non-navigated and navigated group was 7.33 days and 8.33 days, respectively (<em>p</em> = 0.67).<br /><strong>Conclusion:</strong> There was an increase in the proportion of patients who returned for follow-up following abnormal clinical breast examination finding after implementation of the breast navigation programme at AKUH-N.
Collapse
|
57
|
Selby K, Baumgartner C, Levin TR, Doubeni CA, Zauber AG, Schottinger J, Jensen CD, Lee JK, Corley DA. Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests: A Systematic Review. Ann Intern Med 2017; 167:565-575. [PMID: 29049756 PMCID: PMC6178946 DOI: 10.7326/m17-1361] [Citation(s) in RCA: 86] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Fecal immunochemical testing is the most commonly used method for colorectal cancer screening worldwide. However, its effectiveness is frequently undermined by failure to obtain follow-up colonoscopy after positive test results. PURPOSE To evaluate interventions to improve rates of follow-up colonoscopy for adults after a positive result on a fecal test (guaiac or immunochemical). DATA SOURCES English-language studies from the Cochrane Central Register of Controlled Trials, PubMed, and Embase from database inception through June 2017. STUDY SELECTION Randomized and nonrandomized studies reporting an intervention for colonoscopy follow-up of asymptomatic adults with positive fecal test results. DATA EXTRACTION Two reviewers independently extracted data and ranked study quality; 2 rated overall strength of evidence for each category of study type. DATA SYNTHESIS Twenty-three studies were eligible for analysis, including 7 randomized and 16 nonrandomized studies. Three were at low risk of bias. Eleven studies described patient-level interventions (changes to invitation, provision of results or follow-up appointments, and patient navigators), 5 provider-level interventions (reminders or performance data), and 7 system-level interventions (automated referral, precolonoscopy telephone calls, patient registries, and quality improvement efforts). Moderate evidence supported patient navigators and provider reminders or performance data. Evidence for system-level interventions was low. Seventeen studies reported the proportion of test-positive patients who completed colonoscopy compared with a control population, with absolute differences of -7.4 percentage points (95% CI, -19 to 4.3 percentage points) to 25 percentage points (CI, 14 to 35 percentage points). LIMITATION More than half of studies were at high or very high risk of bias; heterogeneous study designs and characteristics precluded meta-analysis. CONCLUSION Patient navigators and giving providers reminders or performance data may help improve colonoscopy rates of asymptomatic adults with positive fecal blood test results. Current evidence about useful system-level interventions is scant and insufficient. PRIMARY FUNDING SOURCE National Cancer Institute. (PROSPERO: CRD42016048286).
Collapse
Affiliation(s)
- Kevin Selby
- From Kaiser Permanente Division of Research, Oakland, California; University of Lausanne, Lausanne, Switzerland; University of California at San Francisco, San Francisco, California; Bern University Hospital, Bern, Switzerland; Kaiser Permanente Medical Center, Walnut Creek, California; University of Pennsylvania, Philadelphia, Pennsylvania; Memorial Sloan Kettering Cancer Center, New York, New York; and Kaiser Permanente, Pasadena, California
| | - Christine Baumgartner
- From Kaiser Permanente Division of Research, Oakland, California; University of Lausanne, Lausanne, Switzerland; University of California at San Francisco, San Francisco, California; Bern University Hospital, Bern, Switzerland; Kaiser Permanente Medical Center, Walnut Creek, California; University of Pennsylvania, Philadelphia, Pennsylvania; Memorial Sloan Kettering Cancer Center, New York, New York; and Kaiser Permanente, Pasadena, California
| | - Theodore R Levin
- From Kaiser Permanente Division of Research, Oakland, California; University of Lausanne, Lausanne, Switzerland; University of California at San Francisco, San Francisco, California; Bern University Hospital, Bern, Switzerland; Kaiser Permanente Medical Center, Walnut Creek, California; University of Pennsylvania, Philadelphia, Pennsylvania; Memorial Sloan Kettering Cancer Center, New York, New York; and Kaiser Permanente, Pasadena, California
| | - Chyke A Doubeni
- From Kaiser Permanente Division of Research, Oakland, California; University of Lausanne, Lausanne, Switzerland; University of California at San Francisco, San Francisco, California; Bern University Hospital, Bern, Switzerland; Kaiser Permanente Medical Center, Walnut Creek, California; University of Pennsylvania, Philadelphia, Pennsylvania; Memorial Sloan Kettering Cancer Center, New York, New York; and Kaiser Permanente, Pasadena, California
| | - Ann G Zauber
- From Kaiser Permanente Division of Research, Oakland, California; University of Lausanne, Lausanne, Switzerland; University of California at San Francisco, San Francisco, California; Bern University Hospital, Bern, Switzerland; Kaiser Permanente Medical Center, Walnut Creek, California; University of Pennsylvania, Philadelphia, Pennsylvania; Memorial Sloan Kettering Cancer Center, New York, New York; and Kaiser Permanente, Pasadena, California
| | - Joanne Schottinger
- From Kaiser Permanente Division of Research, Oakland, California; University of Lausanne, Lausanne, Switzerland; University of California at San Francisco, San Francisco, California; Bern University Hospital, Bern, Switzerland; Kaiser Permanente Medical Center, Walnut Creek, California; University of Pennsylvania, Philadelphia, Pennsylvania; Memorial Sloan Kettering Cancer Center, New York, New York; and Kaiser Permanente, Pasadena, California
| | - Christopher D Jensen
- From Kaiser Permanente Division of Research, Oakland, California; University of Lausanne, Lausanne, Switzerland; University of California at San Francisco, San Francisco, California; Bern University Hospital, Bern, Switzerland; Kaiser Permanente Medical Center, Walnut Creek, California; University of Pennsylvania, Philadelphia, Pennsylvania; Memorial Sloan Kettering Cancer Center, New York, New York; and Kaiser Permanente, Pasadena, California
| | - Jeffrey K Lee
- From Kaiser Permanente Division of Research, Oakland, California; University of Lausanne, Lausanne, Switzerland; University of California at San Francisco, San Francisco, California; Bern University Hospital, Bern, Switzerland; Kaiser Permanente Medical Center, Walnut Creek, California; University of Pennsylvania, Philadelphia, Pennsylvania; Memorial Sloan Kettering Cancer Center, New York, New York; and Kaiser Permanente, Pasadena, California
| | - Douglas A Corley
- From Kaiser Permanente Division of Research, Oakland, California; University of Lausanne, Lausanne, Switzerland; University of California at San Francisco, San Francisco, California; Bern University Hospital, Bern, Switzerland; Kaiser Permanente Medical Center, Walnut Creek, California; University of Pennsylvania, Philadelphia, Pennsylvania; Memorial Sloan Kettering Cancer Center, New York, New York; and Kaiser Permanente, Pasadena, California
| |
Collapse
|
58
|
Molina Y, Kim SJ, Berrios N, Glassgow AE, San Miguel Y, Darnell JS, Pauls H, Vijayasiri G, Warnecke RB, Calhoun EA. Patient Navigation Improves Subsequent Breast Cancer Screening After a Noncancerous Result: Evidence from the Patient Navigation in Medically Underserved Areas Study. J Womens Health (Larchmt) 2017; 27:317-323. [PMID: 28933653 DOI: 10.1089/jwh.2016.6120] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Past efforts to assess patient navigation on cancer screening utilization have focused on one-time uptake, which may not be sufficient in the long term. This is partially due to limited resources for in-person, longitudinal patient navigation. We examine the effectiveness of a low-intensity phone- and mail-based navigation on multiple screening episodes with a focus on screening uptake after receiving noncancerous results during a previous screening episode. METHODS The is a secondary analysis of patients who participated in a randomized controlled patient navigation trial in Chicago. Participants include women referred for a screening mammogram, aged 50-74 years, and with a history of benign/normal screening results. Navigation services focused on identification of barriers and intervention via shared decision-making processes. A multivariable logistic regression intent-to-treat model was used to examine differences in odds of obtaining a screening mammogram within 2 years of the initial mammogram (yes/no) between navigated and non-navigated women. Sensitivity analyses were conducted to explore patterns across subsets of participants (e.g., navigated women successfully contacted before the initial appointment; women receiving care at Hospital C). RESULTS The final sample included 2,536 women (741 navigated, 1,795 non-navigated). Navigated women exhibited greater odds of obtaining subsequent screenings relative to women in the standard care group in adjusted models and analyses including women who received navigation before the initial appointment. CONCLUSIONS Our findings suggest that low-intensity navigation services can improve follow-up screening among women who receive a noncancerous result. Further investigation is needed to confirm navigation's impacts on longitudinal screening.
Collapse
Affiliation(s)
- Yamile Molina
- 1 School of Public Health, Cancer Center, Center for Research on Women and Gender, University of Illinois at Chicago , Chicago, Illinois
| | - Sage J Kim
- 2 School of Public Health, University of Illinois at Chicago , Chicago, Illinois
| | - Nerida Berrios
- 2 School of Public Health, University of Illinois at Chicago , Chicago, Illinois
| | | | - Yazmin San Miguel
- 4 Department of Epidemiology, University of California San Diego, San Diego State University , San Diego, California
| | - Julie S Darnell
- 5 Health Sciences Division, Loyola University , Chicago, Illinois
| | - Heather Pauls
- 6 College of Nursing, University of Illinois at Chicago , Chicago, Illinois
| | - Ganga Vijayasiri
- 7 Institute for Health Research and Policy, University of Illinois at Chicago , Chicago, Illinois
| | - Richard B Warnecke
- 7 Institute for Health Research and Policy, University of Illinois at Chicago , Chicago, Illinois
| | - Elizabeth A Calhoun
- 2 School of Public Health, University of Illinois at Chicago , Chicago, Illinois
- 8 University of Arizona , Tucson, Arizona
| |
Collapse
|
59
|
Abstract
Colorectal cancer (CRC) contributes a major burden of cancer mortality in the United States. There are multiple effective screening approaches that can reduce CRC mortality. These approaches are supported by different levels of evidence, and each has its own advantages and disadvantages. Implementing a systematic approach to screening that addresses the multiple steps involved in the screening process is essential to improving population-level CRC screening. Offering patients stool-based screening is important for increasing screening uptake. However, programs that offer stool testing must support the population health infrastructure needed to promote adherence to repeat testing and follow-up of abnormal tests.
Collapse
Affiliation(s)
- Alison T Brenner
- Cecil G Sheps Center for Health Services Research, University of North Carolina, 725 Martin Luther King Jr Boulevard, CB# 7590, Chapel Hill, NC 27599-7590, USA.
| | - Michael Dougherty
- Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, 4182 Bioinformatics Building, 130 Mason Farm Road, Chapel Hill, NC 27599-6134, USA
| | - Daniel S Reuland
- Division of General Internal Medicine, Department of Medicine, University of North Carolina, 725 Martin Luther King Jr Boulevard, CB# 7590, Chapel Hill, NC 27599-7590, USA
| |
Collapse
|
60
|
Grimes C, Dankovchik J, Cahn M, Warren-Mears V. American Indian and Alaska Native Cancer Patients' Perceptions of a Culturally Specific Patient Navigator Program. J Prim Prev 2017; 38:121-135. [PMID: 27838858 PMCID: PMC5313295 DOI: 10.1007/s10935-016-0458-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Lack of access to care, funding limitations, cultural, and social barriers are challenges specific to tribal communities that have led to adverse cancer outcomes among American Indians/Alaska Natives (AI/AN). While the cancer navigator model has been shown to be effective in other underserved communities, it has not been widely implemented in Indian Country. We conducted in-depth interviews with 40 AI/AN patients at tribal clinics in Idaho and Oregon. We developed the survey instrument in partnership with community members to ensure a culturally appropriate semi-structured questionnaire. Questions explored barriers to accessing care, perceptions of the navigator program, satisfaction, and recommendations. AI/AN cancer patients reported physical, emotional, financial, and transportation barriers to care, but most did not feel there were any cultural barriers to receiving care. Navigator services most commonly used included decision making, referrals, transportation, scheduling appointments, and communication. Satisfaction with the program was high. Our study provides a template to develop a culturally appropriate survey instrument for use with an AI/AN population, which could be adapted for use with other indigenous patient populations. Although our sample was small, our qualitative analysis facilitated a deeper understanding of the barriers faced by this population and how a navigator program may best address them. The results reveal the strengths and weakness of this program, and provide baseline patient satisfaction numbers which will allow future patient navigator programs to better create evaluation benchmarks.
Collapse
Affiliation(s)
- Carol Grimes
- Northwest Portland Area Indian Health Board, 918 NE Rosa Parks Way, Portland, OR, 97211, USA
| | - Jenine Dankovchik
- Northwest Portland Area Indian Health Board, 2121 SW Broadway, Suite 300, Portland, OR, 97201, USA.
| | - Megan Cahn
- College of Public Health and Human Sciences, Oregon State University, 6430 SE Ogden St., Portland, OR, 97206, USA
| | - Victoria Warren-Mears
- Northwest Tribal Epidemiology Center, 2121 SW Broadway, Suite 300, Portland, OR, 97201, USA
| |
Collapse
|
61
|
Krok-Schoen JL, Fisher JL, Baltic RD, Paskett ED. White-Black Differences in Cancer Incidence, Stage at Diagnosis, and Survival Among Older Adults. J Aging Health 2017; 30:863-881. [PMID: 28553811 DOI: 10.1177/0898264317696777] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
OBJECTIVE To identify potential White-Black differences in cancer incidence rates, stage at diagnosis, and relative survival probabilities among older adults using Surveillance, Epidemiology, and End Results (SEER) data. METHOD Differences in cancer incidence, stage at diagnosis, and 5-year relative survival probability were examined for cases diagnosed within the most recent 5-year period and over time for cases diagnosed from 1973 to 2013 (incidence only) for older White and Black adults. RESULTS Among adults aged 65 to 74, 75 to 84, and 85 years and older, Black adults had higher cancer incidence rates per 100,000 than White males from 1973 to 2013, respectively. Late stage and unstaged cancers were more common among Black adults in each of the three age groups compared with Whites. Five-year relative survival probability for all invasive cancers combined was higher for Whites than Blacks in each of the three age groups. DISCUSSION Continued efforts are needed to reduce racial disparities in cancer incidence and mortality among older adults.
Collapse
Affiliation(s)
- Jessica L Krok-Schoen
- 1 Division of Medical Dietetics and Health Sciences, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH, USA.,2 Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - James L Fisher
- 3 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA
| | - Ryan D Baltic
- 2 Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Electra D Paskett
- 2 Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.,4 Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA.,5 Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
| |
Collapse
|
62
|
Ali-Faisal SF, Colella TJF, Medina-Jaudes N, Benz Scott L. The effectiveness of patient navigation to improve healthcare utilization outcomes: A meta-analysis of randomized controlled trials. PATIENT EDUCATION AND COUNSELING 2017; 100:436-448. [PMID: 27771161 DOI: 10.1016/j.pec.2016.10.014] [Citation(s) in RCA: 78] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Revised: 09/09/2016] [Accepted: 10/14/2016] [Indexed: 06/06/2023]
Abstract
OBJECTIVE To determine the effects of patient navigation (PN) on healthcare utilization outcomes using meta-analysis and the quality of evidence. METHODS Medical and social science databases were searched for randomized controlled trials published in English between 1989 and May 2015. The review process was guided by PRISMA. Included studies were assessed for quality using the Downs and Black tool. Data were extracted to assess the effect of navigation on: health screening rates, diagnostic resolution, cancer care follow-up treatment adherence, and attendance of care events. Random-effects models were used to compute risk ratios and I2 statistics determined the impact of heterogeneity. RESULTS Of 3985 articles screened, 25 articles met inclusion criteria. Compared to usual care, patients who received PN were significantly more likely to access health screening (OR 2.48, 95% CI, 1.93-3.18, P<0.00001) and attend a recommended care event (OR 2.55, 95% CI, 1.27-5.10, P<0.01). PN was favoured to increase adherence to cancer care follow-up treatment and obtain diagnoses. Most studies involved trained lay navigators (n=12) compared to health professionals (n=9). CONCLUSION PN is effective to increase screening rates and complete care events. PRACTICE IMPLICATIONS PN is an effective intervention for use in healthcare.
Collapse
Affiliation(s)
- Sobia F Ali-Faisal
- Program in Public Health, Stony Brook Medicine, Stony Brook University, Stony Brook, USA.
| | - Tracey J F Colella
- Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada; University Health Network/Toronto Rehabilitation Cardiovascular Prevention & Rehabilitation Program, Toronto, Canada.
| | - Naomi Medina-Jaudes
- Program in Public Health, Stony Brook Medicine, Stony Brook University, Stony Brook, USA.
| | - Lisa Benz Scott
- Program in Public Health, Stony Brook Medicine, Stony Brook University, Stony Brook, USA; The School of Health Technology & Management, Stony Brook University, Stony Brook, USA.
| |
Collapse
|
63
|
Molina Y, Glassgow AE, Kim SJ, Berrios NM, Pauls H, Watson KS, Darnell JS, Calhoun EA. Patient Navigation in Medically Underserved Areas study design: A trial with implications for efficacy, effect modification, and full continuum assessment. Contemp Clin Trials 2017; 53:29-35. [PMID: 27940186 PMCID: PMC5274626 DOI: 10.1016/j.cct.2016.12.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Revised: 11/30/2016] [Accepted: 12/03/2016] [Indexed: 11/20/2022]
Abstract
BACKGROUND The Patient Navigation in Medically Underserved Areas study objectives are to assess if navigation improves: 1) care uptake and time to diagnosis; and 2) outcomes depending on patients' residential medically underserved area (MUA) status. Secondary objectives include the efficacy of navigation across 1) different points of the care continuum among patients diagnosed with breast cancer; and 2) multiple regular screening episodes among patients who did not obtain breast cancer diagnoses. DESIGN/METHODS Our randomized controlled trial was implemented in three community hospitals in South Chicago. Eligible participants were: 1) female, 2) 18+years old, 3) not pregnant, 4) referred from a primary care provider for a screening or diagnostic mammogram based on an abnormal clinical breast exam. Participants were randomized to 1) control care or 2) receive longitudinal navigation, through treatment if diagnosed with cancer or across multiple years if asymptomatic, by a lay health worker. Participants' residential areas were identified as: 1) established MUA (before 1998), 2) new MUA (after 1998), 3) eligible/but not designated as MUA, and 4) affluent/ineligible for MUA. Primary outcomes include days to initially recommended care after randomization and days to diagnosis for women with abnormal results. Secondary outcomes concern days to treatment initiation following a diagnosis and receipt of subsequent screening following normal/benign results. DISCUSSION This intervention aims to assess the efficacy of patient navigation on breast cancer care uptake across the continuum. If effective, the program may improve rates of early cancer detection and breast cancer morbidity.
Collapse
Affiliation(s)
- Yamile Molina
- University of Illinois at Chicago, 1603 West Taylor Street, Chicago, IL 60622, USA.
| | - Anne E Glassgow
- University of Illinois at Chicago, 1603 West Taylor Street, Chicago, IL 60622, USA
| | - Sage J Kim
- University of Illinois at Chicago, 1603 West Taylor Street, Chicago, IL 60622, USA
| | - Nerida M Berrios
- University of Illinois at Chicago, 1603 West Taylor Street, Chicago, IL 60622, USA
| | - Heather Pauls
- University of Illinois at Chicago, 1603 West Taylor Street, Chicago, IL 60622, USA
| | - Karriem S Watson
- University of Illinois at Chicago, 1603 West Taylor Street, Chicago, IL 60622, USA
| | - Julie S Darnell
- Loyola University Chicago, 1032 W. Sheridan Road, Chicago, IL 60660, USA
| | - Elizabeth A Calhoun
- University of Illinois at Chicago, 1603 West Taylor Street, Chicago, IL 60622, USA; University of Arizona, 550 East Van Buren Street, Phoenix, AZ 85004, USA
| |
Collapse
|
64
|
Harding M. Effect of nurse navigation on patient care satisfaction and distress associated with breast biopsy. Clin J Oncol Nurs 2016; 19:E15-20. [PMID: 25689662 DOI: 10.1188/15.cjon.e15-e20] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Navigation during the biopsy period is a superior approach to delivering care, with those patients receiving services experiencing less distress. Critical nurse navigator roles include providing information and facilitating access to the healthcare system, both of which are influential on distress. The information in this article supports the expansion of navigation programs to include women undergoing biopsy and aids in promoting a higher standard of care. OBJECTIVES To evaluate the effect of navigation on care satisfaction and distress in women undergoing breast biopsy. METHODS A descriptive, cross-sectional survey design from two outpatient radiology clinics in Appalachia was used. FINDINGS Navigated women had lower scores on every distress measure and were less likely to seek information from an outside source. Women who were more satisfied with their care reported decreased distress; the factors influencing distress varied depending on whether they were the recipient of navigation services. In the non-navigated population, general satisfaction with care and accessibility were more likely to influence distress.
Collapse
Affiliation(s)
- Mariann Harding
- School of Nursing, Kent State University at Tuscarawas, New Philadelphia, OH
| |
Collapse
|
65
|
Bukowski A, Gioia S, Chavarri-Guerra Y, Soto-Perez-de-Celis E, St Louis J, Paulino E, Nogueira-Rodrigues A, Goss PE. Patient Navigation to Improve Access to Breast Cancer Care in Brazil. J Glob Oncol 2016; 3:433-437. [PMID: 29094079 PMCID: PMC5646893 DOI: 10.1200/jgo.2016.006726] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Affiliation(s)
- Alexandra Bukowski
- , , and , Avon International Breast Cancer Research Program, Massachusetts General Hospital; , , , , , , , and , The Global Cancer Institute, Boston, MA; and , Instituto Nacional de Câncer José Alencar Gomes da Silva; Rio de Janeiro; , Federal University of Minas Gerais, Belo Horizonte, Brazil; and and , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Sandra Gioia
- , , and , Avon International Breast Cancer Research Program, Massachusetts General Hospital; , , , , , , , and , The Global Cancer Institute, Boston, MA; and , Instituto Nacional de Câncer José Alencar Gomes da Silva; Rio de Janeiro; , Federal University of Minas Gerais, Belo Horizonte, Brazil; and and , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Yanin Chavarri-Guerra
- , , and , Avon International Breast Cancer Research Program, Massachusetts General Hospital; , , , , , , , and , The Global Cancer Institute, Boston, MA; and , Instituto Nacional de Câncer José Alencar Gomes da Silva; Rio de Janeiro; , Federal University of Minas Gerais, Belo Horizonte, Brazil; and and , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Enrique Soto-Perez-de-Celis
- , , and , Avon International Breast Cancer Research Program, Massachusetts General Hospital; , , , , , , , and , The Global Cancer Institute, Boston, MA; and , Instituto Nacional de Câncer José Alencar Gomes da Silva; Rio de Janeiro; , Federal University of Minas Gerais, Belo Horizonte, Brazil; and and , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Jessica St Louis
- , , and , Avon International Breast Cancer Research Program, Massachusetts General Hospital; , , , , , , , and , The Global Cancer Institute, Boston, MA; and , Instituto Nacional de Câncer José Alencar Gomes da Silva; Rio de Janeiro; , Federal University of Minas Gerais, Belo Horizonte, Brazil; and and , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Eduardo Paulino
- , , and , Avon International Breast Cancer Research Program, Massachusetts General Hospital; , , , , , , , and , The Global Cancer Institute, Boston, MA; and , Instituto Nacional de Câncer José Alencar Gomes da Silva; Rio de Janeiro; , Federal University of Minas Gerais, Belo Horizonte, Brazil; and and , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Angelica Nogueira-Rodrigues
- , , and , Avon International Breast Cancer Research Program, Massachusetts General Hospital; , , , , , , , and , The Global Cancer Institute, Boston, MA; and , Instituto Nacional de Câncer José Alencar Gomes da Silva; Rio de Janeiro; , Federal University of Minas Gerais, Belo Horizonte, Brazil; and and , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Paul E Goss
- , , and , Avon International Breast Cancer Research Program, Massachusetts General Hospital; , , , , , , , and , The Global Cancer Institute, Boston, MA; and , Instituto Nacional de Câncer José Alencar Gomes da Silva; Rio de Janeiro; , Federal University of Minas Gerais, Belo Horizonte, Brazil; and and , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| |
Collapse
|
66
|
Shokar NK, Byrd T, Salaiz R, Flores S, Chaparro M, Calderon-Mora J, Reininger B, Dwivedi A. Against colorectal cancer in our neighborhoods (ACCION): A comprehensive community-wide colorectal cancer screening intervention for the uninsured in a predominantly Hispanic community. Prev Med 2016; 91:273-280. [PMID: 27575314 DOI: 10.1016/j.ypmed.2016.08.039] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Revised: 06/17/2016] [Accepted: 08/25/2016] [Indexed: 12/14/2022]
Abstract
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the USA. Screening is widely recommended but underutilized, particularly among the low income, the uninsured, recent immigrants and Hispanics. The study objective was to determine the effectiveness of a comprehensive community-wide, bilingual, CRC screening intervention among uninsured predominantly Hispanic individuals. This prospective study was embedded in a CRC screening program and utilized a quasi-experimental design. Recruitment occurred from Community and clinic sites. Inclusion criteria were aged 50-75years, uninsured, due for CRC screening, Texas address and exclusions were a history of CRC, or recent rectal bleeding. Eligible subjects were randomized to either promotora (P), video (V), or combined promotora and video (PV) education, and also received no-cost screening with fecal immunochemical testing or colonoscopy and navigation. The non-randomly allocated controls recruited from a similar county, received no intervention. The main outcome was 6month self-reported CRC screening. Per protocol and worst case scenario analyses, and logistic regression with covariate adjustment were performed. 784 subjects (467 in intervention group, 317 controls) were recruited; mean age was 56.8years; 78.4% were female, 98.7% were Hispanic and 90.0% were born in Mexico. In the worst case scenario analysis (n=784) screening uptake was 80.5% in the intervention group and 17.0% in the control group [relative risk 4.73, 95% CI: 3.69-6.05, P<0.001]. No educational group differences were observed. Covariate adjustment did not significantly alter the effect. A multicomponent community-wide, bilingual, CRC screening intervention significantly increased CRC screening in an uninsured predominantly Hispanic population.
Collapse
Affiliation(s)
- Navkiran K Shokar
- Department of Family and Community Medicine and Biomedical Sciences, Texas Tech University Health Sciences Center-El Paso, 9849 Kenworthy Street, El Paso, TX 79924, United States.
| | - Theresa Byrd
- Department of Public Health, Texas Tech University Health Sciences Center, 3601 4th Street STOP 9430, Lubbock, TX 79430-9430, United States.
| | - Rebekah Salaiz
- Department of Family and Community Medicine and Biomedical Sciences, Texas Tech University Health Sciences Center-El Paso, 9849 Kenworthy Street, El Paso, TX 79924, United States.
| | - Silvia Flores
- Department of Family and Community Medicine and Biomedical Sciences, Texas Tech University Health Sciences Center-El Paso, 9849 Kenworthy Street, El Paso, TX 79924, United States.
| | - Maria Chaparro
- Department of Family and Community Medicine and Biomedical Sciences, Texas Tech University Health Sciences Center-El Paso, 9849 Kenworthy Street, El Paso, TX 79924, United States.
| | - Jessica Calderon-Mora
- Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, Office of Diversity Affairs, 5001 El Paso Drive, El Paso, TX 79905, United States
| | - Belinda Reininger
- Department of Health Promotion and Behavioral Sciences, University of Texas School of Public Health, Regional Brownsville Campus, 80 Fort Brown, Brownsville, TX 78520, United States.
| | - Alok Dwivedi
- Department of Biomedical Sciences, Texas Tech University Health Sciences Center, 5001 El Paso Drive, El Paso, TX 79905, United States
| |
Collapse
|
67
|
Borrayo EA, Scott KL, Drennen AR, Macdonald T, Nguyen J. Determinants of Treatment Delays among Underserved Hispanics with Lung and Head and Neck Cancers. Cancer Control 2016; 23:390-400. [DOI: 10.1177/107327481602300410] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Background Evidence is lacking to explain the reasons why treatment is delayed among disadvantaged Hispanic patients diagnosed with lung and head and neck cancers. Data indicate that treatment delays beyond 46 days increase the risk of death for individuals with these cancers. Methods A mixed-methods design was used to explore determinants of treatment delays by analyzing data from the medical records of 40 Hispanic patients and data from interviews with 29 Hispanic patients, care-givers, health care professionals, and patient navigators from a safety-net hospital. Results Of the 40 Hispanic patients, 35% initiated treatment 46 days or more after being diagnosed, but women experienced longer delays than men (average of 48 days). Women with few comorbid diseases (≤ 4) were more likely to experience treatment delays. Institutional-related determinants at publicly funded hospitals appear to delay treatment for patients at the safety-net hospital, and patient-related determinants common to underserved patients (eg, no health insurance coverage) are likely to further contribute to these delays. Conclusions Delayed treatment is associated with poor outcomes and low rates of survival in patients with lung and head and neck cancers. Therefore, action should be taken to improve the time between diagnosis and the initiation of treatment for disadvantaged Hispanic patients.
Collapse
Affiliation(s)
- Evelinn A. Borrayo
- Department of Psychology, Salud Family Health Centers, Fort Collins, Colorado
| | - Katie L. Scott
- Colorado State University, Colorado School of Public Health, University of Colorado, Denver, Colorado, Department of Neurology, Salud Family Health Centers, Fort Collins, Colorado
| | - Ava R. Drennen
- Spectrum Health Medical Group, Grand Rapids, Michigan, and the Department of Behavioral Health, Salud Family Health Centers, Fort Collins, Colorado
| | - Tiare Macdonald
- Department of Psychology, Salud Family Health Centers, Fort Collins, Colorado
| | - Jennifer Nguyen
- Department of Psychology, Salud Family Health Centers, Fort Collins, Colorado
| |
Collapse
|
68
|
Whitley EM, Raich PC, Dudley DJ, Freund KM, Paskett ED, Patierno SR, Simon M, Warren-Mears V, Snyder FR. Relation of comorbidities and patient navigation with the time to diagnostic resolution after abnormal cancer screening. Cancer 2016; 123:312-318. [PMID: 27648520 DOI: 10.1002/cncr.30316] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Revised: 07/20/2016] [Accepted: 08/08/2016] [Indexed: 12/16/2022]
Abstract
BACKGROUND Whether patient navigation improves outcomes for patients with comorbidities is unknown. The aims of this study were to determine the effect of comorbidities on the time to diagnostic resolution after an abnormal cancer screening test and to examine whether patient navigation improves the timeliness and likelihood of diagnostic resolution for patients with comorbidities in comparison with no navigation. METHODS A secondary analysis of comorbidity data collected by Patient Navigation Research Program sites using the Charlson Comorbidity Index (CCI) was conducted. The participants were 6,349 patients with abnormal breast, cervical, colon, or prostate cancer screening tests between 2007 and 2011. The intervention was patient navigation or usual care. The CCI data were highly skewed across projects and cancer sites, and the CCI scores were categorized as 0 (CCI score of 0 or no comorbidities identified; 76% of cases); 1 (CCI score of 1; 16% of cases), or 2 (CCI score ≥ 2; 8% of cases). Separate adjusted hazard ratios for each site and cancer type were obtained, and then they were pooled with a meta-analysis random effects methodology. RESULTS Patients with a CCI score ≥ 2 had delayed diagnostic resolution after an abnormal cancer screening test in comparison with those with no comorbidities. Patient navigation reduced delays in diagnostic resolution, with the greatest benefits seen for those with a CCI score ≥ 2. CONCLUSIONS Persons with a CCI score ≥ 2 experienced significant delays in timely diagnostic care in comparison with patients without comorbidities. Patient navigation was effective in reducing delays in diagnostic resolution among those with CCI scores > 1. Cancer 2017;123:312-318. © 2016 American Cancer Society.
Collapse
Affiliation(s)
- Elizabeth M Whitley
- Prevention Services Division, Colorado Department of Public Health and Environment, Denver, Colorado
| | - Peter C Raich
- Denver Health, Denver, Colorado.,University of Colorado Denver, Aurora, Colorado
| | - Donald J Dudley
- Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas.,University of Virginia, Charlottesville, Virginia
| | - Karen M Freund
- Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts
| | - Electra D Paskett
- Division of Cancer Prevention and Control, Department of Internal Medicine, Ohio State University, Columbus, Ohio.,Division of Epidemiology, Ohio State University, Columbus, Ohio.,Comprehensive Cancer Center, Ohio State University, Columbus, Ohio
| | - Steven R Patierno
- George Washington Cancer Institute, Washington, DC.,Duke Cancer Institute, Durham, North Carolina
| | - Melissa Simon
- Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
| | - Victoria Warren-Mears
- Northwest Portland Area Indian Health Board, Northwest Tribal Epidemiology Center, Portland, Oregon
| | | | | |
Collapse
|
69
|
Ko NY, Snyder FR, Raich PC, Paskett ED, Dudley D, Lee JH, Levine PH, Freund KM. Racial and ethnic differences in patient navigation: Results from the Patient Navigation Research Program. Cancer 2016; 122:2715-22. [PMID: 27227342 PMCID: PMC4992408 DOI: 10.1002/cncr.30109] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 03/14/2016] [Accepted: 04/04/2016] [Indexed: 11/09/2022]
Abstract
BACKGROUND Patient navigation was developed to address barriers to timely care and reduce cancer disparities. The current study explored navigation and racial and ethnic differences in time to the diagnostic resolution of a cancer screening abnormality. METHODS The authors conducted an analysis of the multisite Patient Navigation Research Program. Participants with an abnormal cancer screening test were allocated to either navigation or control. The unadjusted median time to resolution was calculated for each racial and ethnic group by navigation and control. Multivariable Cox proportional hazards models were fit, adjusting for sex, age, cancer abnormality type, and health insurance and stratifying by center of care. RESULTS Among a sample of 7514 participants, 29% were non-Hispanic white, 43% were Hispanic, and 28% were black. In the control group, black individuals were found to have a longer median time to diagnostic resolution (108 days) compared with non-Hispanic white individuals (65 days) or Hispanic individuals (68 days) (P<.0001). In the navigated groups, black individuals had a reduction in the median time to diagnostic resolution (97 days) (P<.0001). In the multivariable models, among controls, black race was found to be associated with an increased delay to diagnostic resolution (hazard ratio, 0.77; 95% confidence interval, 0.69-0.84) compared with non-Hispanic white individuals, which was reduced in the navigated arm (hazard ratio, 0.85; 95% confidence interval, 0.77-0.94). CONCLUSIONS Patient navigation appears to have the greatest impact among black patients, who had the greatest delays in care. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2715-2722. © 2016 American Cancer Society.
Collapse
Affiliation(s)
- Naomi Y Ko
- Section of Hematology Oncology, Boston University School of Medicine, 801 Massachusetts Avenue, First Floor, Boston, MA 02118, (617) 638-8036 phone, (617) 638-8096 fax
| | - Frederick R Snyder
- NOVA Research Company, 801 Roeder Road, Suite 700, Silver Spring, MD 20910
| | - Peter C Raich
- Denver Health, Denver, Colorado; and University of Colorado Denver, Aurora, Colorado, 94 High Meadow Dr., Dillon, CO 80435, (970)468-4763
| | - Electra D. Paskett
- Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, 1590 North High Street, Columbus, OH 43201, (614) 293-3917 phone, (614) 293-5611 fax
| | - Donald Dudley
- Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, (434) 243-6790
| | - Ji-Hyun Lee
- University of New Mexico Comprehensive Cancer Center, University of New Mexico School of Medicine, 1 University of New Mexico, Albuquerque, New Mexico 87131-0001, Phone: 505-272-3718
| | - Paul H. Levine
- The George Washington University School of Public Health; and Health Services; and The George Washington Cancer Institute, 950 New Hampshire Ave. NW 5th Floor, Washington, DC 20052, (202) 994-5330
| | - Karen M Freund
- Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, 35 Kneeland Street, Boston, Massachusetts 02111
| |
Collapse
|
70
|
Battaglia TA, Darnell JS, Ko N, Snyder F, Paskett ED, Wells KJ, Whitley EM, Griggs JJ, Karnad A, Young H, Warren-Mears V, Simon MA, Calhoun E. The impact of patient navigation on the delivery of diagnostic breast cancer care in the National Patient Navigation Research Program: a prospective meta-analysis. Breast Cancer Res Treat 2016; 158:523-34. [PMID: 27432417 PMCID: PMC5216421 DOI: 10.1007/s10549-016-3887-8] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Accepted: 06/17/2016] [Indexed: 11/26/2022]
Abstract
Patient navigation is emerging as a standard in breast cancer care delivery, yet multi-site data on the impact of navigation at reducing delays along the continuum of care are lacking. The purpose of this study was to determine the effect of navigation on reaching diagnostic resolution at specific time points after an abnormal breast cancer screening test among a national sample. A prospective meta-analysis estimated the adjusted odds of achieving timely diagnostic resolution at 60, 180, and 365 days. Exploratory analyses were conducted on the pooled sample to identify which groups had the most benefit from navigation. Clinics from six medical centers serving vulnerable populations participated in the Patient Navigation Research Program. Women with an abnormal breast cancer screening test between 2007 and 2009 were included and received the patient navigation intervention or usual care. Patient navigators worked with patients and their care providers to address patient-specific barriers to care to prevent delays in diagnosis. A total of 4675 participants included predominantly racial/ethnic minorities (74 %) with public insurance (40 %) or no insurance (31 %). At 60 days and 180 days, there was no statistically significant effect of navigation on achieving timely diagnostic care, but a benefit of navigation was seen at 365 days (aOR 2.12, CI 1.36-3.29). We found an equal benefit of navigation across all groups, regardless of race/ethnicity, language, insurance status, and type of screening abnormality. Patient navigation resulted in more timely diagnostic resolution at 365 days among a diverse group of minority, low-income women with breast cancer screening abnormalities. Trial registrations clinicaltrials.gov Identifiers: NCT00613275, NCT00496678, NCT00375024, NCT01569672.
Collapse
Affiliation(s)
- Tracy A Battaglia
- Women's Health Unit, Section of General Internal Medicine, Boston Medical Center and Boston University School of Medicine, 801 Massachusetts Avenue, Crosstown Building 1st Floor, Boston, MA, 02118, USA.
| | - Julie S Darnell
- Department of Public Health Sciences, Stritch School of Medicine, Loyola University Chicago, 2160 S. First Avenue, Bldg 115, Room 556, Maywood, IL, 60153, USA
| | - Naomi Ko
- Section of Hematology Oncology, Boston University School of Medicine, 801 Massachusetts Avenue, First Floor, Boston, MA, 02118, USA
| | - Fred Snyder
- NOVA Research Company, 801 Roeder Road, Suite 700, Silver Spring, MD, 20910, USA
| | - Electra D Paskett
- Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine and Comprehensive Cancer Center, The Ohio State University, 1590 North High Street, Columbus, OH, 43201, USA
| | - Kristen J Wells
- Department of Psychology, San Diego State University, 6363 Alvarado Ct., Ste. 103, San Diego, CA, 92120-4913, USA
| | - Elizabeth M Whitley
- Colorado Department of Public Health and Environment, 4300 Cherry Creek Drive South, Denver, CO, 80246, USA
| | - Jennifer J Griggs
- University of Michigan School of Public Health, 2800 Plymouth Road, Building 16, 116 W, Ann Arbor, MI, 48109, USA
| | - Anand Karnad
- Division of Hematology-Oncology, Cancer Therapy & Research Center (CTRC), UT Health Science Center, 7979 Wurzbach Rd., San Antonio, TX, 78229, USA
| | - Heather Young
- George Washington University Cancer Institute, 950 New Hampshire Ave. NW 5th Floor, Washington, DC, 20052, USA
| | - Victoria Warren-Mears
- Northwest Portland Area Indian Health Board, 2121 SW Broadway, Suite 300, Portland, OR, 97201, USA
| | - Melissa A Simon
- Northwestern University Feinberg School of Medicine, 633 N. St Clair, Suite 1800, Chicago, IL, 60611, USA
| | - Elizabeth Calhoun
- University of Arizona Health Sciences, 550 East Van Buren, Phoenix, AZ, 85004-2230, USA
| |
Collapse
|
71
|
Diagnostic colonoscopy following a positive fecal occult blood test in community health center patients. Cancer Causes Control 2016; 27:881-7. [PMID: 27228991 DOI: 10.1007/s10552-016-0763-0] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 05/13/2016] [Indexed: 01/07/2023]
Abstract
PURPOSE Fecal occult blood testing (FOBT) is a pragmatic screening option for many community health centers (CHCs), but FOBT screening programs will not reduce mortality if patients with positive results do not undergo diagnostic colonoscopy (DC). This study was conducted to investigate DC completion among CHC patients. METHODS This retrospective cohort study used data from three CHCs in the Midwest and Southwest. The primary study outcome was DC completion within 6 months of positive FOBT among adults age 50-75. Patient data was collected using automated electronic queries. Manual chart reviews were conducted if queries produced no evidence of DC. Poisson regression models described adjusted relative risks (RRs) of DC completion. RESULTS The study included 308 patients; 63.3 % were female, 48.7 % were Spanish speakers and 35.7 % were uninsured. Based on combined query and chart review findings, 51.5 % completed DC. Spanish speakers were more likely than English speakers to complete DC [RR 1.19; 95 % confidence interval (CI) 1.04-1.36; P = 0.009], and DC completion was lower among patients with 0 visits than those with 1-2 visits (RR 2.81; 95% CI 1.83-4.33; P < 0.001) or ≥3 visits (RR 3.06; 95% CI 1.57-5.95; P = 0.001). CONCLUSIONS DC completion was low overall, which raises concerns about whether FOBT can reduce CRC mortality in practice. Further research is needed to understand whether CHC navigator programs can achieve very high DC rates. If organizations use FOBT as their primary CRC screening approach and a substantial number of patients receive positive results, both screening rates and DC rates should be measured.
Collapse
|
72
|
Oppong BA, Dash C, Coleman T, Torres T, Adams-Campbell LL. Time to Diagnostic Evaluation After Mammographic Screening in an Urban Setting. J Womens Health (Larchmt) 2016; 25:1225-1230. [PMID: 27182625 DOI: 10.1089/jwh.2015.5661] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The Capital Breast Care Center (CBCC), a screening facility established to serve minority women, developed a culturally sensitive patient care paradigm that would address concerns of adherence to follow-up of abnormal results after initial mammogram. Women with abnormal mammograms are assigned a Black or Latina navigator who facilitates the additional workup needed by scheduling follow-up, arranging transportation, providing counsel/emotional support, and even accompanying them to diagnostic imaging or biopsy appointment. We present data on follow-up rates after breast cancer screening. METHODS All patients seen at CBCC are entered into a prospectively collected database. We calculated intervals (in days) between the screening and diagnostic visits. Descriptive statistics and median time to follow-up are reported. Differences between Black and Hispanic women on time interval were tested by t-test. RESULTS From January 2010 to December 2012, 4605 digital screening mammograms were performed. Fifty-two percent of the women self-identified as Black, 41% as Hispanic, 4% White, 2% Asian, and 1% as "other." Of the screening studies, 451 (9.8%) required additional workup, out of which 362 (80%) of the women returned for the recommended diagnostic imaging. The median interval between screening and diagnostic imaging was 39 days (range: 6-400). Of the 162 women recommended to have a core needle biopsy, 81.5% underwent biopsy within a median of 21 days (range: 0-221 days). CONCLUSION At the CBCC, time to patient follow-up after initial mammographic screening is within the CDC-recommended performance standard of less than 60 days. For a population that historically has low rates of clinical follow-up, we attribute this reduction in delays to breast cancer diagnostic resolution to a culturally sensitive patient navigation program. Additional studies are needed to assess how the existing navigation program can be individualized/tailored to target the remaining 20% of women who did not adhere to the recommended workup.
Collapse
Affiliation(s)
- Bridget A Oppong
- 1 Breast Division, Department of Surgery, MedStar Georgetown University Hospital , Washington, District of Columbia.,2 Georgetown University Lombardi Comprehensive Cancer Center , Washington, District of Columbia
| | - Chiranjeev Dash
- 2 Georgetown University Lombardi Comprehensive Cancer Center , Washington, District of Columbia
| | - Tesha Coleman
- 3 Capital Breast Care Center, Georgetown Lombardi Comprehensive Cancer Center , Washington, District of Columbia
| | - Tanya Torres
- 3 Capital Breast Care Center, Georgetown Lombardi Comprehensive Cancer Center , Washington, District of Columbia
| | - Lucile L Adams-Campbell
- 2 Georgetown University Lombardi Comprehensive Cancer Center , Washington, District of Columbia
| |
Collapse
|
73
|
de la Riva EE, Hajjar N, Tom LS, Phillips S, Dong X, Simon MA. Providers' Views on a Community-Wide Patient Navigation Program: Implications for Dissemination and Future Implementation. Health Promot Pract 2016; 17:382-90. [PMID: 27009130 PMCID: PMC5600160 DOI: 10.1177/1524839916628865] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The DuPage Patient Navigation Collaborative (DPNC) adapted and scaled the Patient Navigation Research Program's intervention model to navigate uninsured suburban DuPage County women with an abnormal breast or cervical cancer screening result. Recent findings reveal the effectiveness of the DPNC in addressing patient risk factors for delayed follow-up, but gaps remain as patient measures may not adequately capture navigator impact. Using semistructured interviews with 19 DPNC providers (representing the county health department, clinics, advocacy organizations, and academic partners), this study explores the critical roles of the DPNC in strengthening community partnerships and enhancing clinical services. Findings from these provider interviews revealed that a wide range of resources existed within DuPage but were often underused. Providers indicated that the DPNC was instrumental in fostering community partnerships and that navigators enhanced the referral processes, communications, and service delivery among clinical teams. Providers also recommended expanding navigation to mental health, women's health, and for a variety of chronic conditions. Considering that many in the United States have recently gained access to the health care system, clinical teams might benefit by incorporating navigators who serve a dual working purpose embedded in the community and clinics to enhance the service delivery for vulnerable populations.
Collapse
Affiliation(s)
| | | | - Laura S Tom
- Northwestern University-Feinberg School of Medicine, Chicago, IL, USA
| | - Sara Phillips
- Northwestern University-Feinberg School of Medicine, Chicago, IL, USA
| | - XinQi Dong
- Rush University Medical Center, Chicago, IL, USA
| | - Melissa A Simon
- Northwestern University-Feinberg School of Medicine, Chicago, IL, USA Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
| |
Collapse
|
74
|
Wells KJ, Winters PC, Jean-Pierre P, Warren-Mears V, Post D, Van Duyn MAS, Fiscella K, Darnell J, Freund KM. Effect of patient navigation on satisfaction with cancer-related care. Support Care Cancer 2016; 24:1729-53. [PMID: 26438146 PMCID: PMC4767607 DOI: 10.1007/s00520-015-2946-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 09/14/2015] [Indexed: 10/23/2022]
Abstract
PURPOSE Despite growing popularity of patient navigation (PN) as a means to improve cancer care quality and reduce cancer-related disparities, there are few well-designed controlled trials assessing the impact of PN on patient outcomes like satisfaction with care. The present controlled study examined effect of PN on satisfaction with cancer-related care. METHODS Patients who presented with a symptom or abnormal screening test (n = 1788) or definitive diagnosis (n = 445) of breast, cervical, colorectal, or prostate cancer from eight Patient Navigator Research Program sites were included in one of two groups: intervention (PN) or comparison (usual care or usual care plus cancer educational materials). Trained patient navigators met with intervention group participants to help them assess and identify resources to address barriers to cancer diagnostic or treatment care. Using a validated instrument, we assessed participants' satisfaction with their cancer diagnostic or treatment care up to 3 months after diagnostic resolution of a cancer-related abnormality or within 3 months of initiation of cancer treatment. RESULTS Overall, patients reported high satisfaction with diagnostic care and cancer treatment. There were no statistically significant differences between PN and control groups in satisfaction with cancer-related care (p > 0.05). Hispanic and African American participants were less likely to report high satisfaction with cancer care when compared to White patients. Middle-aged participants with higher education, higher household income, private insurance, owning their own home, working full-time, and those whose primary language is English had higher satisfaction with cancer-related diagnostic care. CONCLUSIONS PN had no statistically significant effect on patients' satisfaction with cancer-related care. Further research is needed to define the patient populations who might benefit from PN, content of PN that is most useful, and services that might enhance PN. TRIAL REGISTRATIONS clinicaltrials.gov identifiers: NCT00613275 , NCT00496678 , NCT00375024 , NCT01569672.
Collapse
Affiliation(s)
- Kristen J Wells
- Department of Psychology, San Diego State University and University of California, San Diego Moores Cancer Center, 6363 Alvarado Court, Suite 103, San Diego, CA, 92120-1863, USA.
| | - Paul C Winters
- Family Medicine Research Programs, University of Rochester Medical Center, 1381 South Avenue, Rochester, NY, 14620, USA
| | - Pascal Jean-Pierre
- Department of Psychology, University of Notre Dame, 109 Haggar Hall, Notre Dame, IN, 46556, USA
| | - Victoria Warren-Mears
- Northwest Portland Area Indian Health Board, 2121 SW Broadway Suite 300, Portland, OR, 97201, USA
| | - Douglas Post
- Ohio State University, 1590 North High Street, Suite 525, Columbus, OH, 43201, USA
| | - Mary Ann S Van Duyn
- National Institutes of Health, National Cancer Institute, 9609 Medical Center Drive, Room 6W118, Bethesda, MD, 20892, USA
| | - Kevin Fiscella
- Family Medicine Research Programs, University of Rochester Medical Center, 1381 South Avenue, Rochester, NY, 14620, USA
| | - Julie Darnell
- Division of Health Policy & Administration, School of Public Health, University of Illinois at Chicago, 1603 W. Taylor Street, Room 758, Chicago, IL, 60612, USA
| | - Karen M Freund
- Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Tufts University School of Medicine, 800 Washington Street #63, Boston, MA, 02111, USA
| |
Collapse
|
75
|
Krok-Schoen JL, Oliveri JM, Paskett ED. Cancer Care Delivery and Women's Health: The Role of Patient Navigation. Front Oncol 2016; 6:2. [PMID: 26858934 PMCID: PMC4729879 DOI: 10.3389/fonc.2016.00002] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Accepted: 01/03/2016] [Indexed: 01/09/2023] Open
Abstract
Background Patient navigation (PN) is a patient-centered health-care service delivery model that assists individuals, particularly the medically underserved, in overcoming barriers (e.g., personal, logistical, and system) to care across the cancer care continuum. In 2012, the American College of Surgeons Commission on Cancer (CoC) announced that health-care facilities seeking CoC-accreditation must have PN processes in place starting January 1, 2015. The CoC mandate, in light of the recent findings from centers within the Patient Navigation Research Program and the influx of PN interventions, warrants the present literature review. Methods PubMed and Medline were searched for studies published from January 2010 to October 2015, particularly those recent articles within the past 2 years, addressing PN for breast and gynecological cancers, and written in English. Search terms included patient navigation, navigation, navigator, cancer screening, clinical trials, cancer patient, cancer survivor, breast cancer, gynecological cancer, ovarian cancer, uterine cancer, vaginal cancer, and vulvar cancer. Results Consistent with prior reviews, PN was shown to be effective in helping women who receive cancer screenings, receive more timely diagnostic resolution after a breast and cervical cancer screening abnormality, initiate treatment sooner, receive proper treatment, and improve quality of life after cancer diagnosis. However, several limitations were observed. The majority of PN interventions focused on cancer screening and diagnostic resolution for breast cancer. As observed in prior reviews, methodological rigor (e.g., randomized controlled trial design) was lacking. Conclusion Future research opportunities include testing PN interventions in the post-treatment settings and among gynecological cancer patient populations, age-related barriers to effective PN, and collaborative efforts between community health workers and patient navigators as care goes across segments of the cancer control continuum. As PN programs continue to develop and become a standard of care, further research will be required to determine the effectiveness of cancer PN across the cancer care continuum, and in different patient populations.
Collapse
Affiliation(s)
| | - Jill M Oliveri
- Comprehensive Cancer Center, The Ohio State University , Columbus, OH , USA
| | - Electra D Paskett
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA
| |
Collapse
|
76
|
Ustjanauskas AE, Bredice M, Nuhaily S, Kath L, Wells KJ. Training in Patient Navigation: A Review of the Research Literature. Health Promot Pract 2015; 17:373-81. [PMID: 26656600 DOI: 10.1177/1524839915616362] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Despite the proliferation of patient navigation programs designed to increase timely receipt of health care, little is known about the content and delivery of patient navigation training, or best practices in this arena. The current study begins to address these gaps in understanding, as it is the first study to comprehensively review descriptions of patient navigation training in the peer-reviewed research literature. Seventy-five patient navigation efficacy studies published since 1995, identified through PubMed and by the authors, were included in this narrative review. Fifty-nine of the included studies (79%) mentioned patient navigation training, and 55 of these studies additionally provided a description of training. Most studies did not thoroughly document patient navigation training practices. Additionally, several topics integral to the role of patient navigators, as well as components of training central to successful adult learning, were not commonly described in the research literature. Descriptions of training also varied widely across studies in terms of duration, location, format, learning strategies employed, occupation of trainer, and content. These findings demonstrate the need for established standards of navigator training as well as for future research on the optimal delivery and content of patient navigation training.
Collapse
Affiliation(s)
- Amy E Ustjanauskas
- University of California, San Diego Moores Cancer Center, San Diego, CA, USA San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA
| | | | | | - Lisa Kath
- San Diego State University, San Diego, CA, USA
| | - Kristen J Wells
- University of California, San Diego Moores Cancer Center, San Diego, CA, USA San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA San Diego State University, San Diego, CA, USA
| |
Collapse
|
77
|
Dissemination of patient navigation programs across the United States. JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE 2015; 20:E15-24. [PMID: 24858322 DOI: 10.1097/phh.0b013e3182a505ec] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To use diffusion and dissemination frameworks to describe how indicators of economic and health care disparity affect the location and type of patient navigation programs. METHODS A cross-sectional national Web-based survey conducted during 2009-2010 with support from 65 separate national and regional stakeholder organizations. PARTICIPANTS A total of 1116 self-identified patient navigators across the United States. MAIN OUTCOME MEASURE The location and characteristics of patient navigation programs according to economic and health care disparity indicators. RESULTS Patient navigation programs appear to be geographically dispersed across the United States. Program differences were observed in navigator type, population served, and setting by poverty level. Programs in high-poverty versus low-poverty areas were more likely to use lay navigators (P < .001) and to be located in community health centers and agencies with religious affiliations (50.6 vs 36.4%, and 21.5% vs 16.7%. respectively; P ≤ 0.01). CONCLUSION(S) Results suggest that navigation programs have spread beyond initial target inception areas and also serve as a potentially important resource in communities with higher levels of poverty and/or relatively low access to care. In addition, while nurse navigators have emerged as a significant component of the patient navigation workforce, lay health navigators serve a vital role in underserved communities. Other factors from dissemination frameworks may influence the spread of navigation and provide useful insights to support the dissemination of programs to areas of high need.
Collapse
|
78
|
Baker DW, Brown T, Goldman SN, Liss DT, Kollar S, Balsley K, Lee JY, Buchanan DR. Two-year follow-up of the effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers. Cancer Causes Control 2015; 26:1685-90. [PMID: 26337733 DOI: 10.1007/s10552-015-0650-0] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Accepted: 08/03/2015] [Indexed: 02/02/2023]
Abstract
PURPOSE We previously found that a multifaceted outreach intervention achieved 82 % annual adherence to colorectal cancer (CRC) screening with fecal occult blood testing (FOBT). This study assessed adherence to FOBT after a second outreach. METHODS We followed 225 patients in community health centers in Chicago, Illinois, who were randomized to the intervention group. Our primary analysis focused on 124 patients who completed FOBT during the first outreach and were due again for annual FOBT; 90% were Latino, 87% preferred to speak Spanish, and 77% were uninsured. Second outreach consisted of (1) a mailed reminder letter, a free fecal immunochemical test (FIT) with postage-paid return envelope, (2) automated phone and text messages, (3) automated reminders 2 weeks later if the FIT was not returned, and (4) a telephone call after 3 months. Our main outcome was completion of FIT within 6 months of the due date. We also analyzed the proportion of the original 225 patients who were fully screened for CRC over the 2-year study period. RESULTS A total of 88.7% of patients completed a FIT within 6 months of their second outreach. Over the 2 years since the first outreach, 71.6% of the 225 patients assigned to the intervention group were fully up to date on CRC screening, another 11.1% had been screened suboptimally, and 17.3% were inadequately screened or not screened. CONCLUSIONS It is possible to achieve high rates of CRC screening over a 2-year period for vulnerable populations using outreach with FIT as a primary strategy.
Collapse
Affiliation(s)
- David W Baker
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL, 60611, USA. .,Center for Advancing Equity in Clinical Preventive Services, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. .,Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA. .,Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
| | - Tiffany Brown
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL, 60611, USA. .,Center for Advancing Equity in Clinical Preventive Services, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
| | - Shira N Goldman
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL, 60611, USA. .,Center for Advancing Equity in Clinical Preventive Services, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
| | - David T Liss
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL, 60611, USA. .,Center for Advancing Equity in Clinical Preventive Services, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
| | | | | | - Ji Young Lee
- Division of General Internal Medicine and Geriatrics, Department of Medicine, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL, 60611, USA. .,Center for Advancing Equity in Clinical Preventive Services, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
| | | |
Collapse
|
79
|
Ramachandran A, Snyder FR, Katz ML, Darnell JS, Dudley DJ, Patierno SR, Sanders MR, Valverde PA, Simon MA, Warren-Mears V, Battaglia TA. Barriers to health care contribute to delays in follow-up among women with abnormal cancer screening: Data from the Patient Navigation Research Program. Cancer 2015; 121:4016-24. [PMID: 26385420 DOI: 10.1002/cncr.29607] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Revised: 06/18/2015] [Accepted: 06/22/2015] [Indexed: 12/11/2022]
Abstract
BACKGROUND There is limited understanding of the association between barriers to care and clinical outcomes within patient navigation programs. METHODS Secondary analyses of data from the intervention arms of the Patient Navigation Research Program were performed, which included navigated participants with abnormal breast and cervical cancer screening tests from 2007 to 2010. Independent variables were: 1) the number of unique barriers to care (0, 1, 2, or ≥3) documented during patient navigation encounters; and 2) the presence of socio-legal barriers originating from social policy (yes/no). The median time to diagnostic resolution of index screening abnormalities was estimated using Kaplan-Meier cumulative incidence curves. Multivariable Cox proportional hazards regression examined the impact of barriers on time to resolution, controlling for sociodemographics and stratifying by study center. RESULTS Among 2600 breast screening participants, approximately 75% had barriers to care documented (25% had 1 barrier, 16% had 2 barriers, and 34% had ≥3 barriers). Among 1387 cervical screening participants, greater than one-half had barriers documented (31% had 1 barrier, 11% had 2 barriers, and 13% had ≥3 barriers). Among breast screening participants, the presence of barriers was associated with less timely resolution for any number of barriers compared with no barriers. Among cervical screening participants, only the presence of ≥2 barriers was found to be associated with less timely resolution. Both types of barriers, socio-legal and other barriers, were found to be associated with delay among breast and cervical screening participants. CONCLUSIONS Navigated women with barriers resolved cancer screening abnormalities at a slower rate compared with navigated women with no barriers. Further innovations in navigation care are necessary to maximize the impact of patient navigation programs nationwide.
Collapse
Affiliation(s)
- Ambili Ramachandran
- Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
| | | | - Mira L Katz
- College of Public Health, The Ohio State University, Columbus, Ohio
| | - Julie S Darnell
- School of Public Health, University of Illinois at Chicago, Chicago, Illinois
| | - Donald J Dudley
- Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, Virginia
| | - Steven R Patierno
- Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina
| | - Mechelle R Sanders
- Department of Family Medicine, University of Rochester, Rochester, New York
| | - Patricia A Valverde
- Colorado School of Public Health, University of Colorado at Denver, Denver, Colorado
| | - Melissa A Simon
- Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Victoria Warren-Mears
- Northwest Portland Area Indian Health Board, Northwest Tribal Epidemiology Center, Portland, Oregon
| | - Tracy A Battaglia
- Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
| | | |
Collapse
|
80
|
Levinson AH, Valverde P, Garrett K, Kimminau M, Burns EK, Albright K, Flynn D. Community-based navigators for tobacco cessation treatment: a proof-of-concept pilot study among low-income smokers. BMC Public Health 2015; 15:627. [PMID: 26155841 PMCID: PMC5477807 DOI: 10.1186/s12889-015-1962-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Accepted: 06/23/2015] [Indexed: 12/05/2022] Open
Abstract
BACKGROUND A majority of continuing smokers in the United States are socioeconomically disadvantaged (SED) adults, who are less likely than others to achieve and maintain abstinence despite comparable quit-attempt rates. A national research initiative seeks effective new strategies for increasing successful smoking cessation outcomes among SED populations. There is evidence that chronic and acute stressors may interfere with SED smokers who try to quit on their own. Patient navigators have been effectively used to improve adherence to chronic disease treatment. We designed and have pilot-tested an innovative, non-clinical community-based intervention--smoking cessation treatment navigators--to determine feasibility (acceptance, adherence, and uncontrolled results) for evaluation by randomized controlled trial (RCT). METHODS The intervention was developed for smokers among parents and other household members of inner city pre-school for low-income children. Smoking cessation treatment navigators were trained and deployed to help participants choose and adhere to evidence-based cessation treatment (EBCT). Navigators provided empathy, resource-linking, problem-solving, and motivational reinforcement. Measures included rates of study follow-up completion, EBCT utilization, navigation participation, perceived intervention quality, 7-day point abstinence and longest abstinence at three months. Both complete-case and intent-to-treat analyses were performed. RESULTS Eighty-five percent of study participants (n = 40) completed final data collection. More than half (53%) enrolled in a telephone quitline and nearly three-fourths (71%) initiated nicotine replacement therapy. Participants completed a mean 3.4 navigation sessions (mean 30 min duration) and gave the intervention very high quality and satisfaction ratings. Self-reported abstinence was comparable to rates for evidence-based cessation strategies (21% among study completers, 18% using intent-to-treat analysis; median 21 days abstinent among relapsers). CONCLUSIONS The pilot results suggest that smoking cessation treatment navigators are feasible to study in community settings and are well-accepted for increasing use of EBCT among low-income smokers. Randomized controlled trial for efficacy is warranted.
Collapse
Affiliation(s)
- Arnold H Levinson
- Department of Community & Behavioral Health, Colorado School of Public Health, Aurora, CO, USA.
- University of Colorado Cancer Center, Mail Stop F542, 13001 East 17th Place, 80045, Aurora, CO, USA.
| | - Patricia Valverde
- Department of Community & Behavioral Health, Colorado School of Public Health, Aurora, CO, USA.
| | - Kathleen Garrett
- Department of Community & Behavioral Health, Colorado School of Public Health, Aurora, CO, USA.
| | - Michele Kimminau
- University of Colorado Cancer Center, Mail Stop F542, 13001 East 17th Place, 80045, Aurora, CO, USA.
| | - Emily K Burns
- Mercy Family Medicine, Mercy Regional Medical Center, Centura Health, Durango, CO, USA.
| | - Karen Albright
- Department of Community & Behavioral Health, Colorado School of Public Health, Aurora, CO, USA.
| | | |
Collapse
|
81
|
Goebel M, Singal AG, Nodora J, Castañeda SF, Martinez E, Doubeni C, Laiyemo A, Gupta S. How can we boost colorectal and hepatocellular cancer screening among underserved populations? Curr Gastroenterol Rep 2015; 17:22. [PMID: 26031831 PMCID: PMC8248527 DOI: 10.1007/s11894-015-0445-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Colorectal cancer (CRC) and hepatocellular carcinoma (HCC) are common causes of cancer incidence and mortality in the USA, particularly among underserved populations such as racial/ethnic minorities, the under-/uninsured, and individuals with low socioeconomic status. Although screening can reduce cancer-related mortality, participation is suboptimal among underserved populations, likely serving as the largest contributor to observed inequities in HCC and CRC outcomes among US populations. In this narrative review, we highlight inequities across populations in the USA with respect to incidence and mortality for CRC and HCC and highlight potential causes, with a focus on screening rates. In addition, drawing from the recent literature, we highlight promising strategies for increasing screening for HCC and CRC and propose future research and policy solutions to optimize screening rates. With focused implementation of screening strategies and novel research, the burden of HCC and CRC can be reduced among underserved populations.
Collapse
Affiliation(s)
- Melissa Goebel
- Cancer Prevention and Control Program, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA,
| | | | | | | | | | | | | | | |
Collapse
|
82
|
Shokar NK, Byrd T, Lairson DR, Salaiz R, Kim J, Calderon-Mora J, Nguyen N, Ortiz M. Against Colorectal Cancer in Our Neighborhoods, a Community-Based Colorectal Cancer Screening Program Targeting Low-Income Hispanics. Health Promot Pract 2015; 16:656-66. [DOI: 10.1177/1524839915587265] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Background. Colorectal cancer is the second leading cause of cancer-related death in the United States. Despite universal screening recommendations, screening rates in the United States remain suboptimal, especially among the poor, the uninsured, recent immigrants, and Hispanics. This article describes the development of a large community-based colorectal cancer screening program designed to address these disparities. Method. The Against Colorectal Cancer in our Neighborhoods program is a bilingual, evidence-based, theory-guided, multicomponent community screening intervention, targeting the uninsured and developed using a systematic planning process. It combines community health worker–led outreach, bilingual and culturally tailored community education, and no-cost screening with provision of the fecal immunochemical test or colonoscopy and navigation services. A detailed process and outcome evaluation is planned. Program development cost calculated prospectively (in 2011 dollars) using a societal perspective and micro-costing methods was $243,278, of which $180,344 was direct cost. Discussion. The detailed description of the development processes and costs of this health promotion program targeting low-income Hispanics will inform health program decision makers about the resource requirements for planning and developing new programs to reduce disease burden in communities.
Collapse
Affiliation(s)
| | - Theresa Byrd
- Texas Tech University Health Sciences Center, El Paso, TX, USA
| | | | - Rebekah Salaiz
- Texas Tech University Health Sciences Center, El Paso, TX, USA
| | - Junghyun Kim
- University of Texas Health Science Center at Houston, TX, USA
| | | | | | - Melchor Ortiz
- Texas Tech University Health Sciences Center, El Paso, TX, USA
| |
Collapse
|
83
|
Krok-Schoen JL, Brewer BM, Young GS, Weier RC, Tatum CM, DeGraffinreid CR, Paskett ED. Participants' barriers to diagnostic resolution and factors associated with needing patient navigation. Cancer 2015; 121:2757-64. [PMID: 25921981 DOI: 10.1002/cncr.29414] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Revised: 03/30/2015] [Accepted: 03/30/2015] [Indexed: 11/08/2022]
Abstract
BACKGROUND Patient navigation (PN) may improve cancer care by identifying and removing patient-reported barriers to care. In 2012, the American College of Surgeons Commission on Cancer (CoC) announced that health care facilities seeking CoC accreditation must have PN processes in place by January 1, 2015. Given these unfunded mandates, hospitals are looking for cost-effective ways to implement PN. This study examined demographic and psychosocial predictors of barriers to diagnostic resolution among individuals with a cancer screening abnormality enrolled in the Ohio Patient Navigation Research Project. METHODS Data were obtained from patients who received care at 1 of 9 Ohio Patient Navigation Research Project intervention clinics. Descriptive statistics and logistic regression models were used. RESULTS There were 424 participants, and 151 (35.6%) reported a barrier to diagnostic resolution within 90 days of study consent. The most commonly reported barriers were misconceptions about a test or treatment (16.4%), difficulty in communicating with the provider (15.0%), and scheduling problems (11.5%). Univariate analyses indicated that race, education, employment, income, insurance, clinic type, friend support, and physical and psychological functioning were significantly associated with reporting a barrier to diagnostic resolution. Multivariate analyses found that comorbidities (odds ratio, 1.65; 95% confidence interval, 1.04-2.61) and higher intrusive thoughts and feelings (odds ratio, 1.25; 95% confidence interval, 1.10-1.41) were significantly associated with reporting a barrier to diagnostic resolution. CONCLUSIONS The results suggest that demographic and psychosocial factors are associated with barriers to diagnostic resolution. To ensure compliance with the CoC mandate and provide timely care to all patients, CoC-accredited facilities can systematically identify the patients most likely to have barriers to care and assign them to PN.
Collapse
Affiliation(s)
| | | | - Gregory S Young
- Center for Biostatistics, Ohio State University, Columbus, Ohio
| | - Rory C Weier
- Comprehensive Cancer Center, Ohio State University, Columbus, Ohio
| | - Cathy M Tatum
- Comprehensive Cancer Center, Ohio State University, Columbus, Ohio
| | | | - Electra D Paskett
- Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.,Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio.,Division of Epidemiology, College of Public Health, Ohio State University, Columbus, Ohio
| |
Collapse
|
84
|
Pelto DJ, Sly JR, Winkel G, Redd W, Thompson HS, Itzkowitz SH, Jandorf L. Predicting Colonoscopy Completion Among African American and Latino/a Participants in a Patient Navigation Program. J Racial Ethn Health Disparities 2015; 2:101-11. [PMID: 25893157 PMCID: PMC4399963 DOI: 10.1007/s40615-014-0053-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Patient navigation (PN) effectively increases screening colonoscopy (SC) rates, a key to reducing deaths from colorectal cancer (CRC). Ethnic minority populations have disproportionately low SC rates and high CRC mortality rates and, therefore, especially stand to benefit from PN. Adapting the Health Belief Model as an explanatory model, the current analysis examined predictors of SC rates in two randomized studies that used PN to increase SC among 411 African American and 461 Latino/a patients at a large urban medical center. Speaking Spanish but not English (odds ratio (OR), 2.192; p < 0.005), having a higher income (OR, 1.218; p < 0.005), and scoring higher on the Pros of Colonoscopy scale (OR, 1.535; p = 0.023) independently predicted colonoscopy completion. Health education and PN programs that increase awareness of the benefits of getting a colonoscopy may encourage colonoscopy completion. In the context of language-appropriate PN programs for African American and Latino/a individuals, those with lower incomes and English speakers may require additional education and counseling to support their decision-making around colonoscopy.
Collapse
|
85
|
Simon MA, Tom LS, Nonzee NJ, Murphy KR, Endress R, Dong X, Feinglass J. Evaluating a bilingual patient navigation program for uninsured women with abnormal screening tests for breast and cervical cancer: implications for future navigator research. Am J Public Health 2015; 105:e87-94. [PMID: 25713942 DOI: 10.2105/ajph.2014.302341] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES The DuPage Patient Navigation Collaborative evaluated the Patient Navigation Research Program (PNRP) model for uninsured women receiving free breast or cervical cancer screening through the Illinois Breast and Cervical Cancer Program in DuPage County, Illinois. METHODS We used medical records review and patient surveys of 477 women to compare median follow-up times with external Illinois Breast and Cervical Cancer Program and Chicago PNRP benchmarks of performance. We examined the extent to which we mitigated community-defined timeliness risk factors for delayed follow-up, with a focus on Spanish-speaking participants. RESULTS Median follow-up time (29.0 days for breast and 56.5 days for cervical screening abnormalities) compared favorably to external benchmarks. Spanish-speaking patients had lower health literacy, lower patient activation, and more health care system distrust than did English-speaking patients, but despite the prevalence of timeliness risk factors, we observed no differences in likelihood of delayed (> 60 days) follow-up by language. CONCLUSIONS Our successful replication and scaling of the PNRP navigation model to DuPage County illustrates a promising approach for future navigator research.
Collapse
Affiliation(s)
- Melissa A Simon
- Melissa A. Simon is with the Departments of Obstetrics and Gynecology and Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, and the Robert H. Lurie Comprehensive Cancer Center, Chicago. Laura S. Tom and Narissa J. Nonzee are with the Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University. Kara R. Murphy and Richard Endress are with Access DuPage, Wheaton, IL. XinQi Dong is with the Institute for Healthy Aging, Rush University Medical Center, Chicago. Joe Feinglass is with the Departments of General Internal Medicine and Geriatrics and Preventive Medicine, Feinberg School of Medicine, Northwestern University
| | | | | | | | | | | | | |
Collapse
|
86
|
Percac-Lima S, Cronin PR, Ryan DP, Chabner BA, Daly EA, Kimball AB. Patient navigation based on predictive modeling decreases no-show rates in cancer care. Cancer 2015; 121:1662-70. [PMID: 25585595 DOI: 10.1002/cncr.29236] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Accepted: 11/21/2014] [Indexed: 12/26/2022]
Abstract
BACKGROUND Patient adherence to appointments is key to improving outcomes in health care. "No-show" appointments contribute to suboptimal resource use. Patient navigation and telephone reminders have been shown to improve cancer care and adherence, particularly in disadvantaged populations, but may not be cost-effective if not targeted at the appropriate patients. METHODS In 5 clinics within a large academic cancer center, patients who were considered to be likely (the top 20th percentile) to miss a scheduled appointment without contacting the clinic ahead of time ("no-shows") were identified using a predictive model and then randomized to an intervention versus a usual-care group. The intervention group received telephone calls from a bilingual patient navigator 7 days before and 1 day before the appointment. RESULTS Over a 5-month period, of the 40,075 appointments scheduled, 4425 patient appointments were deemed to be at high risk of a "no-show" event. After the patient navigation intervention, the no-show rate in the intervention group was 10.2% (167 of 1631), compared with 17.5% in the control group (280 of 1603) (P<.001). Reaching a patient or family member was associated with a significantly lower no-show rate (5.9% and 3.0%, respectively; P<.001 and .006, respectively) compared with leaving a message (14.7%: P = .117) or no contact (no-show rate, 21.6%: P = .857). CONCLUSIONS Telephone navigation targeted at those patients predicted to be at high risk of visit nonadherence was found to effectively and substantially improve patient adherence to cancer clinic appointments. Further studies are needed to determine the long-term impact on patient outcomes, but short-term gains in the optimization of resources can be recognized immediately.
Collapse
Affiliation(s)
- Sanja Percac-Lima
- Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts; Center for Community Health Improvement, Massachusetts General Hospital, Boston, Massachusetts
| | | | | | | | | | | |
Collapse
|
87
|
Percac-Lima S, Ashburner JM, McCarthy AM, Piawah S, Atlas SJ. Patient navigation to improve follow-up of abnormal mammograms among disadvantaged women. J Womens Health (Larchmt) 2014; 24:138-43. [PMID: 25522246 DOI: 10.1089/jwh.2014.4954] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND Patient navigation (PN) can improve breast cancer care among disadvantaged women. We evaluated the impact of a PN program on follow-up after an abnormal mammogram. METHODS Between 2007 and 2010, disadvantaged women with an abnormal mammogram (Breast Imaging-Reporting and Data System [BI-RADS] codes 0, 3, 4, 5) cared for in a community health center (CHC) with PN were compared to those receiving care in 11 network practices without PN. Multivariable logistic regression and Cox proportional hazards modeling were used to compare the percentages receiving appropriate follow-up and time to follow-up between the groups. RESULTS Abnormal mammography findings were reported for 132 women in the CHC with PN and 168 from practices without PN. The percentage of women with appropriate follow-up care was higher in the practice with PN than in non-PN practices (90.4% vs. 75.3%, adjusted p=0.006). RESULTS varied by BI-RADS score for women in PN and non-PN practices (BI-RADS 0, 93.7% vs. 90.2%, p=0.24; BI-RADS 3, 85.7% vs. 49.2%, p=0.003; BI-RADS 4/5, 95.1% vs. 82.8%, p=0.26). Time to follow-up was similar for BI-RADS 0 and occurred sooner for women in the PN practice than in non-PN practices for BI-RADS 3 and 4/5 (BI-RADS 3, adjusted hazard ratio [aHR], 95% confidence interval [CI]: 2.41 [1.36-4.27], BI-RADS 4/5, aHR [95% CI]: 1.41 [0.88-2.24]). CONCLUSIONS Disadvantaged women from a CHC with PN were more likely to receive appropriate follow-up after an abnormal mammogram than were those from practices without PN. Expanding PN to include all disadvantaged women within primary care networks could improve equity in cancer care.
Collapse
Affiliation(s)
- Sanja Percac-Lima
- 1 Chelsea HealthCare Center, Massachusetts General Hospital , Chelsea, Massachusetts
| | | | | | | | | |
Collapse
|
88
|
Ramachandran A, Freund KM, Bak SM, Heeren TC, Chen CA, Battaglia TA. Multiple barriers delay care among women with abnormal cancer screening despite patient navigation. J Womens Health (Larchmt) 2014; 24:30-6. [PMID: 25513858 DOI: 10.1089/jwh.2014.4869] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND While there is widespread dissemination of patient navigation programs in an effort to reduce delays in cancer care, little is known about the impact of barriers to care on timely outcomes. METHODS We conducted a secondary analysis of the Boston Patient Navigation Research Program (PNRP) to examine the effect that the presence of barriers had on time to diagnostic resolution of abnormal breast or cervical cancer screening tests. We used multivariable Cox proportional hazards regression with time to diagnostic resolution as the outcome to examine the effect of the number of barriers, controlling for demographic covariates and clustered by patients' primary navigator. RESULTS There were 1481 women who received navigation; mean age was 39 years; 32% were White, 27% Black, and 31% Hispanic; 28% had private health insurance; and 38% did not speak English. Overall, half (n=745, 50%) had documentation of one or more barriers to care. Women with barriers were more likely to be older, non-White, non-English language speakers, and on public or no health insurance compared with women without barriers. In multivariable analyses, we found less timely diagnostic resolution as the number of barriers increased (one barrier, adjusted hazard ratio [aHR] 0.81 [95% CI 0.56-1.17], p=0.26; two barriers, aHR 0.55 [95% CI 0.37-0.81], p=0.0025; three or more barriers, aHR 0.31 [95% CI 0.21-0.46], p<0.0001)]. CONCLUSION Within a patient navigation program proven to reduce delays in care, we found that navigated patients with documented barriers to care experience less timely resolution of abnormal cancer screening tests.
Collapse
Affiliation(s)
- Ambili Ramachandran
- 1 Women's Health Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine , Boston, Massachusetts
| | | | | | | | | | | |
Collapse
|
89
|
Community low-dose CT lung cancer screening: a prospective cohort study. Lung 2014; 193:135-9. [PMID: 25503535 DOI: 10.1007/s00408-014-9671-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2014] [Accepted: 12/01/2014] [Indexed: 12/17/2022]
Abstract
BACKGROUND The National Lung Screening Trial (NLST) in 2011 showed that low-dose CT (LDCT) screening in high-risk groups reduces lung cancer deaths. Major professional organizations, as well as the U.S. Preventative Services Task Force, have endorsed LDCT screening in these select populations. However, major questions remain about whether widespread deployment of CT screening can achieve results similar to the NLST, especially in the community setting. METHODS A prospective cohort study was initiated in November 2010. Participants at least 50 years old and with at least 20 pack-years of smoking history underwent LDCT screening in a community setting. RESULTS One hundred and fifty four participants underwent LDCT screening with median follow-up of 2.7 years. Compared with the NLST, there was a higher rate of positive screening tests (35.7 vs. 27.3 %), higher false positive rate (100 vs. 96.4 %), and poor adherence (43 vs. 95 %). Invasive diagnostic follow-up was uncommon and uncomplicated. No interval lung cancer was detected. Late follow-up was mostly attributed to participant or primary care provider preference (67.5 %), participants lost to follow-up (17.5 %), and lack of insurance (10 %). CONCLUSIONS These findings highlight the potential challenges of generalizing the NLST mortality benefits in the broad deployment of CT screening. Our results support current recommendations that LDCT screening be performed in a highly structured and integrated setting.
Collapse
|
90
|
Reiter PL, Katz ML, Young GS, Paskett ED. Predictors of resolution in navigated patients with abnormal cancer screening tests. THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY 2014; 12:431-8. [PMID: 26288850 PMCID: PMC4545214 DOI: 10.12788/jcso.0094] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 09/14/2014] [Indexed: 11/20/2022]
Abstract
BACKGROUND Patient navigation has been effective in improving cancer care, yet little is known about what predicts timely outcomes in navigated patients. OBJECTIVE To identify predictors of resolution of abnormal cancer screening tests in patients who received navigation. METHODS We examined data on patients with abnormal breast (n = 256) or cervical (n = 150) screening tests or symptoms who received navigation as part of the Ohio Patient Navigator Research Program during 2007-2010. We used multivariable Cox proportional hazards regression models to identify predictors of time to resolution (ie, when a patient's clinical abnormality or abnormal screening test was determined to be a benign condition or a cancer diagnosis). RESULTS The median time to resolution was 183 days for navigated patients with breast abnormalities and 172 days for navigated patients with cervical abnormalities. In patients with breast abnormalities, those who reported at least 1 barrier to care during navigation (HR, 0.66; 95% CI, 0.51-0.86) or higher perceived stress (HR, 0.90; 95% CI, 0.82-0.98) had slower resolution. Among patients with cervical abnormalities, those who reported at least 1 barrier to care during navigation had slower resolution (HR, 0.62; 95% CI, 0.42-0.91). Patients with cervical abnormalities had faster resolution if they had private health insurance, but this effect was present only in younger women (interaction 𝑃 = .003). LIMITATIONS Unknown generalizability of results because patients were female and from clinics in central Ohio. CONCLUSIONS Several variables predicted whether patient navigation led to faster resolution, and predictors differed somewhat by disease site. Results will be useful in improving current patient navigation programs and designing future programs.
Collapse
Affiliation(s)
- Paul L Reiter
- Division of Cancer Prevention and Control, College of Medicine; Comprehensive Cancer Center; College of Public Health; The Ohio State University, Columbus, Ohio, USA.
| | - Mira L Katz
- Division of Cancer Prevention and Control, College of Medicine; Comprehensive Cancer Center; College of Public Health; The Ohio State University, Columbus, Ohio, USA
| | - Gregory S Young
- Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA
| | - Electra D Paskett
- Division of Cancer Prevention and Control, College of Medicine; Comprehensive Cancer Center; College of Public Health; The Ohio State University, Columbus, Ohio, USA
| |
Collapse
|
91
|
Results of nurse navigator follow-up after positive colorectal cancer screening test: a randomized trial. J Am Board Fam Med 2014; 27:789-95. [PMID: 25381076 PMCID: PMC4278960 DOI: 10.3122/jabfm.2014.06.140125] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Follow-up after a positive colorectal cancer screening test is necessary for screening to be effective. We hypothesized that nurse navigation would increase the completion of colonoscopy after a positive screening test. METHODS This study was conducted between 2008 and 2012 at 21 primary care medical centers in western Washington State. Participants in the Systems of Support to Increase Colorectal Cancer Screening study who had a positive fecal occult blood test (FOBT) or flexible sigmoidoscopy needing follow-up were randomized to usual care (UC) or a nurse navigator (navigation). UC included an electronic health record-based positive FOBT registry and physician reminder system. Navigation included UC plus care coordination and patient self-management support from a registered nurse who tracked and assisted patients until they completed or refused colonoscopy. The primary outcome was completion of colonoscopy within 6 months. After 6 months, both groups received navigation. RESULTS We randomized 147 participants with a positive FOBT or sigmoidoscopy. Completion of colonoscopy was higher in the intervention group at 6 months, but differences were not statistically significant (91.0% in navigation group vs 80.8% in UC group; adjusted difference, 10.1%; P = .10). Reasons for no or late colonoscopies included refusal, failure to schedule or missed appointments, concerns about risks or costs, and competing health concerns. CONCLUSIONS Navigation did not lead to a statistically significant incremental benefit at 6 months. IMPACT Follow-up rates after a positive colorectal cancer (CRC) screening test are high in a health care system where UC included a registry and physician reminders. Because of high follow-up rates in a health care system where UC included a registry and physician reminders, and small sample size, we cannot rule out incremental benefits of nurse navigation.
Collapse
|
92
|
Zapka JM, Edwards HM, Chollette V, Taplin SH. Follow-up to abnormal cancer screening tests: considering the multilevel context of care. Cancer Epidemiol Biomarkers Prev 2014; 23:1965-73. [PMID: 25073625 PMCID: PMC4191903 DOI: 10.1158/1055-9965.epi-14-0454] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
The call for multilevel interventions to improve the quality of follow-up to abnormal cancer screening has been out for a decade, but published work emphasizes individual approaches, and conceptualizations differ regarding the definition of levels. To investigate the scope and methods being undertaken in this focused area of follow-up to abnormal tests (breast, colon, cervical), we reviewed recent literature and grants (2007-2012) funded by the National Cancer Institute. A structured search yielded 16 grants with varying definitions of "follow-up" (e.g., completion of recommended tests, time to diagnosis); most included minority racial/ethnic group participants. Ten grants concentrated on measurement/intervention development and 13 piloted or tested interventions (categories not mutually exclusive). All studies considered patient-level factors and effects. Although some directed interventions at provider levels, few measured group characteristics and effects of interventions on the providers or levels other than the patient. Multilevel interventions are being proposed, but clarity about endpoints, definition of levels, and measures is needed. The differences in the conceptualization of levels and factors that affect practice need empirical exploration, and we need to measure their salient characteristics to advance our understanding of how context affects cancer care delivery in a changing practice and policy environment.
Collapse
Affiliation(s)
- Jane M Zapka
- Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.
| | - Heather M Edwards
- Clinical Research Directorate/CMRP, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland
| | - Veronica Chollette
- Process of Care Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
| | - Stephen H Taplin
- Process of Care Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
| |
Collapse
|
93
|
Gunn CM, Clark JA, Battaglia TA, Freund KM, Parker VA. An assessment of patient navigator activities in breast cancer patient navigation programs using a nine-principle framework. Health Serv Res 2014; 49:1555-77. [PMID: 24820445 PMCID: PMC4213049 DOI: 10.1111/1475-6773.12184] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
OBJECTIVE To determine how closely a published model of navigation reflects the practice of navigation in breast cancer patient navigation programs. DATA SOURCE Observational field notes describing patient navigator activities collected from 10 purposefully sampled, foundation-funded breast cancer navigation programs in 2008-2009. STUDY DESIGN An exploratory study evaluated a model framework for patient navigation published by Harold Freeman by using an a priori coding scheme based on model domains. DATA COLLECTION Field notes were compiled and coded. Inductive codes were added during analysis to characterize activities not included in the original model. PRINCIPAL FINDINGS Programs were consistent with individual-level principles representing tasks focused on individual patients. There was variation with respect to program-level principles that related to program organization and structure. Program characteristics such as the use of volunteer or clinical navigators were identified as contributors to patterns of model concordance. CONCLUSIONS This research provides a framework for defining the navigator role as focused on eliminating barriers through the provision of individual-level interventions. The diversity observed at the program level in these programs was a reflection of implementation according to target population. Further guidance may be required to assist patient navigation programs to define and tailor goals and measurement to community needs.
Collapse
Affiliation(s)
- Christine M Gunn
- Department of Health Policy and Management, Boston University School of Public HealthBoston, MA
- Women’s Health Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of MedicineBoston, MA
| | - Jack A Clark
- Department of Health Policy and Management, Boston University School of Public HealthBoston, MA
- Center for Healthcare Organization and Implementation Research (CHOIR), VA HSR&DBoston, MA
| | - Tracy A Battaglia
- Women’s Health Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of MedicineBoston, MA
| | - Karen M Freund
- Tufts University School of Medicine, Institute for Clinical Research and Health Policy Studies, Tufts Medical CenterBoston, MA
| | - Victoria A Parker
- Department of Health Policy and Management, Boston University School of Public HealthBoston, MA
| |
Collapse
|
94
|
Gabitova G, Burke NJ. Improving healthcare empowerment through breast cancer patient navigation: a mixed methods evaluation in a safety-net setting. BMC Health Serv Res 2014; 14:407. [PMID: 25234963 PMCID: PMC4177686 DOI: 10.1186/1472-6963-14-407] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2013] [Accepted: 09/15/2014] [Indexed: 12/02/2022] Open
Abstract
Background Breast cancer mortality rates in the U.S. remain relatively high, particularly among ethnic minorities and low-income populations. Unequal access to quality care, lower follow up rates, and poor treatment adherence contribute to rising disparities among these groups. Healthcare empowerment (HCE) is theorized to improve patient outcomes through collaboration with providers and improving understanding of and compliance with treatment. Patient navigation is a health care organizational intervention that essentially improves healthcare empowerment by providing informational, emotional, and psychosocial support. Patient navigators address barriers to care through multilingual coordination of treatment and incorporation of access to community services, support, and education into the continuum of cancer care. Methods Utilizing survey and qualitative methods, we evaluated the patient navigation program in a Northern California safety-net hospital Breast Clinic by assessing its impact on patients’ experiences with cancer care and providers’ perspectives on the program. We conducted qualitative interviews with 16 patients and 4 service providers, conducted approximately 66 hours of clinic observations, and received feedback through the self-administered survey from 66 patients. Results The role of the patient navigator at the Breast Clinic included providing administrative assistance, psychosocial support, improved knowledge, better understanding of treatment process, and ensuring better communication between patients and providers. As such, patient navigators facilitated improved collaboration between patients and providers and understanding of interdisciplinary care processes. The survey results suggested that the majority of patients across all ethnic backgrounds and age groups were highly satisfied with the program and had a positive perception of their navigator. Interviews with patients and providers highlighted the roles of a navigator in ensuring continuity of care, improving treatment completion rates, and reducing providers’ workload and waiting time. Uncertainty about the navigator’s role among the patients was a weakness of the program. Conclusions Patient navigation in the Breast Clinic had a positive impact on patients’ experiences with care and healthcare empowerment. Clarifying uncertainties about the navigators’ role would aid successful outcomes.
Collapse
Affiliation(s)
| | - Nancy J Burke
- Department of Anthropology, History, and Social Medicine and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
| |
Collapse
|
95
|
Ko NY, Darnell JS, Calhoun E, Freund KM, Wells KJ, Shapiro CL, Dudley DJ, Patierno SR, Fiscella K, Raich P, Battaglia TA. Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program. J Clin Oncol 2014. [PMID: 25071111 DOI: 10.1200/jco.2013.53.6037.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Poor and underserved women face barriers in receiving timely and appropriate breast cancer care. Patient navigators help individuals overcome these barriers, but little is known about whether patient navigation improves quality of care. The purpose of this study is to examine whether navigated women with breast cancer are more likely to receive recommended standard breast cancer care. PATIENTS AND METHODS Women with breast cancer who participated in the national Patient Navigation Research Program were examined to determine whether the care they received included the following: initiation of antiestrogen therapy in patients with hormone receptor-positive breast cancer; initiation of postlumpectomy radiation therapy; and initiation of chemotherapy in women younger than age 70 years with triple-negative tumors more than 1 cm. This is a secondary analysis of a multicenter quasi-experimental study funded by the National Cancer Institute to evaluate patient navigation. Multiple logistic regression was performed to compare differences in receipt of care between navigated and non-navigated participants. RESULTS Among participants eligible for antiestrogen therapy, navigated participants (n = 380) had a statistically significant higher likelihood of receiving antiestrogen therapy compared with non-navigated controls (n = 381; odds ratio [OR], 1.73; P = .004) in a multivariable analysis. Among the participants eligible for radiation therapy after lumpectomy, navigated participants (n = 255) were no more likely to receive radiation (OR, 1.42; P = .22) than control participants (n = 297). CONCLUSION We demonstrate that navigated participants were more likely than non-navigated participants to receive antiestrogen therapy. Future studies are required to determine the full impact patient navigation may have on ensuring that vulnerable populations receive quality care.
Collapse
Affiliation(s)
- Naomi Y Ko
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
| | - Julie S Darnell
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Elizabeth Calhoun
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Karen M Freund
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Kristin J Wells
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Charles L Shapiro
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Donald J Dudley
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Steven R Patierno
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Kevin Fiscella
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Peter Raich
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Tracy A Battaglia
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| |
Collapse
|
96
|
Affiliation(s)
- Beverly B Green
- Group Health Cooperative, Seattle, Washington2Group Health Research Institute, Seattle, Washington
| | - Gloria D Coronado
- Kaiser Permanente Center for Health Research Northwest, Portland, Oregon
| |
Collapse
|
97
|
Ko NY, Darnell JS, Calhoun E, Freund KM, Wells KJ, Shapiro CL, Dudley DJ, Patierno SR, Fiscella K, Raich P, Battaglia TA. Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program. J Clin Oncol 2014; 32:2758-64. [PMID: 25071111 DOI: 10.1200/jco.2013.53.6037] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Poor and underserved women face barriers in receiving timely and appropriate breast cancer care. Patient navigators help individuals overcome these barriers, but little is known about whether patient navigation improves quality of care. The purpose of this study is to examine whether navigated women with breast cancer are more likely to receive recommended standard breast cancer care. PATIENTS AND METHODS Women with breast cancer who participated in the national Patient Navigation Research Program were examined to determine whether the care they received included the following: initiation of antiestrogen therapy in patients with hormone receptor-positive breast cancer; initiation of postlumpectomy radiation therapy; and initiation of chemotherapy in women younger than age 70 years with triple-negative tumors more than 1 cm. This is a secondary analysis of a multicenter quasi-experimental study funded by the National Cancer Institute to evaluate patient navigation. Multiple logistic regression was performed to compare differences in receipt of care between navigated and non-navigated participants. RESULTS Among participants eligible for antiestrogen therapy, navigated participants (n = 380) had a statistically significant higher likelihood of receiving antiestrogen therapy compared with non-navigated controls (n = 381; odds ratio [OR], 1.73; P = .004) in a multivariable analysis. Among the participants eligible for radiation therapy after lumpectomy, navigated participants (n = 255) were no more likely to receive radiation (OR, 1.42; P = .22) than control participants (n = 297). CONCLUSION We demonstrate that navigated participants were more likely than non-navigated participants to receive antiestrogen therapy. Future studies are required to determine the full impact patient navigation may have on ensuring that vulnerable populations receive quality care.
Collapse
Affiliation(s)
- Naomi Y Ko
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO.
| | - Julie S Darnell
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Elizabeth Calhoun
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Karen M Freund
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Kristin J Wells
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Charles L Shapiro
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Donald J Dudley
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Steven R Patierno
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Kevin Fiscella
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Peter Raich
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| | - Tracy A Battaglia
- Naomi Y. Ko and Tracy A. Battaglia, Boston University School of Medicine; Karen M. Freund, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA; Julie S. Darnell and Elizabeth Calhoun, School of Public Health, University of Illinois at Chicago, Chicago, IL; Kristin J. Wells, San Diego State University and Moores Cancer Center, San Diego, CA; Charles L. Shapiro, Ohio State University Comprehensive Cancer Center and Wexner Medical Center, Columbus, OH; Donald J. Dudley, University of Texas Health Science Center, San Antonio, TX; Steven R. Patierno, The George Washington University Cancer Institute, Washington, DC; Steven R. Patierno, Duke Cancer Institute, Durham, NC; Kevin Fiscella, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY; and Peter Raich, Denver Health and University of Colorado Denver, Denver, CO
| |
Collapse
|
98
|
Freund KM, Battaglia TA, Calhoun E, Darnell JS, Dudley DJ, Fiscella K, Hare ML, LaVerda N, Lee JH, Levine P, Murray DM, Patierno SR, Raich PC, Roetzheim RG, Simon M, Snyder FR, Warren-Mears V, Whitley EM, Winters P, Young GS, Paskett ED. Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. J Natl Cancer Inst 2014; 106:dju115. [PMID: 24938303 DOI: 10.1093/jnci/dju115] [Citation(s) in RCA: 194] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Patient navigation is a promising intervention to address cancer disparities but requires a multisite controlled trial to assess its effectiveness. METHODS The Patient Navigation Research Program compared patient navigation with usual care on time to diagnosis or treatment for participants with breast, cervical, colorectal, or prostate screening abnormalities and/or cancers between 2007 and 2010. Patient navigators developed individualized strategies to address barriers to care, with the focus on preventing delays in care. To assess timeliness of diagnostic resolution, we conducted a meta-analysis of center- and cancer-specific adjusted hazard ratios (aHRs) comparing patient navigation vs usual care. To assess initiation of cancer therapy, we calculated a single aHR, pooling data across all centers and cancer types. We conducted a metaregression to evaluate variability across centers. All statistical tests were two-sided. RESULTS The 10521 participants with abnormal screening tests and 2105 with a cancer or precancer diagnosis were predominantly from racial/ethnic minority groups (73%) and publically insured (40%) or uninsured (31%). There was no benefit during the first 90 days of care, but a benefit of navigation was seen from 91 to 365 days for both diagnostic resolution (aHR = 1.51; 95% confidence interval [CI] = 1.23 to 1.84; P < .001)) and treatment initiation (aHR = 1.43; 95% CI = 1.10 to 1.86; P < .007). Metaregression revealed that navigation had its greatest benefits within centers with the greatest delays in follow-up under usual care. CONCLUSIONS Patient navigation demonstrated a moderate benefit in improving timely cancer care. These results support adoption of patient navigation in settings that serve populations at risk of being lost to follow-up.
Collapse
Affiliation(s)
- Karen M Freund
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Tracy A Battaglia
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Elizabeth Calhoun
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Julie S Darnell
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Donald J Dudley
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Kevin Fiscella
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Martha L Hare
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Nancy LaVerda
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Ji-Hyun Lee
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Paul Levine
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - David M Murray
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Steven R Patierno
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Peter C Raich
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Richard G Roetzheim
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Melissa Simon
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Frederick R Snyder
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Victoria Warren-Mears
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Elizabeth M Whitley
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Paul Winters
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Gregory S Young
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | - Electra D Paskett
- Affiliations of authors: Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, Comprehensive Cancer Center (EDP), and Center for Biostatistics (GSY), The Ohio State University, Columbus, OH; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (KMF); Women's Health Unit, Section of General Internal Medicine, Evans Department of Medicine, Boston Medical Center and Women's Health Interdisciplinary Research Center, Boston University School of Medicine, Boston, MA (TAB); Division of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL (EC, JSD); Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX (DLD); Department of Family Medicine and Public Health Sciences and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY (KF); Center to Reduce Cancer Health Disparities, National Cancer Institute (MLH), and Biostatistics and Bioinformatics Branch, Division of Epidemiology, Statistics, and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (DMM), Rockville, MD (MLH); George Washington University School of Public Health and Health Services, Washington, DC (NL, PL); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J-HL, RGR); George Washington Cancer Institute, Washington, DC (PL. SRP); Duke Cancer Institute, Durham, NC (SRP); Denver Health, Denver, CO (PCR, EMW); University of Colorado Denver, Aurora, CO (PCR); Department of Family Medicine, University of South Florida, Tampa, FL (RGR); Department of Obstetrics and Gynecology and Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (MS); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL (MS); Clinical Research Ser
| | | |
Collapse
|
99
|
Manca DP, Greiver M, Carroll JC, Salvalaggio G, Cave A, Rogers J, Pencharz J, Aguilar C, Barrett R, Bible S, Grunfeld E. Finding a BETTER way: a qualitative study exploring the prevention practitioner intervention to improve chronic disease prevention and screening in family practice. BMC FAMILY PRACTICE 2014; 15:66. [PMID: 24720686 PMCID: PMC4101848 DOI: 10.1186/1471-2296-15-66] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/24/2013] [Accepted: 04/07/2014] [Indexed: 11/10/2022]
Abstract
Background Our randomized controlled trial (The BETTER Trial) found that training a clinician to become a Prevention Practitioner (PP) in family practices improved chronic disease prevention and screening (CDPS). PPs were trained on CDPS and provided prevention prescriptions tailored to participating patients. For this embedded qualitative study, we explored perceptions of this new role to understand the PP intervention. Methods We used grounded theory methodology and purposefully sampled participants involved in any capacity with the BETTER Trial. Two physicians and one coordinator in each of two cities (Toronto, Ontario and Edmonton, Alberta) conducted eight individual semi-structured interviews and seven focus groups. We used an interview guide and documented research activities through an audit trail, journals, field notes and memos. We analyzed the data using the constant comparative method throughout open coding followed by theoretical coding. Results A framework and process involving external and internal practice facilitation using the new role of PP was thought to impact CDPS. The PP facilitated CDPS through on-going relationships with patients and practice team members. Key components included: 1) approaching CDPS in a comprehensive manner, 2) an individualized and personalized approach at multiple levels, 3) integrated continuity that included linking the patients and practices to CPDS resources, and 4) adaptability to different practices and settings. Conclusions The BETTER framework and key components are described as impacting CDPS through a process that involved a new role, the PP. The introduction of a novel role of a clinician within the primary care practice with skills in CDPS could appropriately address gaps in prevention and screening.
Collapse
Affiliation(s)
- Donna Patricia Manca
- Department of Family Medicine, University of Alberta, University of Alberta, 901 College Plaza, Edmonton, Alberta, T6G 2C8, Canada.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
100
|
Tools to expedite the development of treatment plans. Qual Manag Health Care 2014; 23:70-5. [PMID: 24710182 DOI: 10.1097/qmh.0000000000000020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Quality improvement strategies can be used to modify existing health care processes to reduce patient wait times. We undertook a quality improvement project to reduce the time between new patients' initial visits and the finalization of their treatment plans. Initiation of treatment of new patients at the MD Anderson Sarcoma Medical Oncology Clinic can take up to 2 weeks from their initial consultation. Treatment delays result in increased costs and anxiety for the patient, adversely affecting the quality of care provided. We performed detailed process mapping and a cause-and-effect analysis to identify and prioritize opportunities for improvement. Process improvements addressed 2 key causes of delay to develop a finalized treatment plan: (1) insufficient data for decision making at the time of new patient visit and (2) delays in obtaining diagnostic imaging. After implementing our process improvements, the median time to develop a treatment plan decreased by 89% from 70.5 to 7.6 hours. Our process changes involved minimal additional work and had the secondary outcome of resulting in time savings for the clinic team.
Collapse
|